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ABSTRACT
Evaluating the Cost-Effectiveness of St. John's Wort versus Fluoxetine
for the Treatment of Mild to Moderate Depression
Lee Ann Thayer
The objective of this study was to determine the cost-effectiveness of St. John's Wort
compared to fluoxetine from a third party perspective for the treatment of mild to
moderate depression. Fluoxetine 20 mg daily was compared to St. John's Wort 300 mg
thrice daily in a decision tree modeling depression management in the outpatient setting.
Probabilities were obtained from a Medline search as well as input from an expert panel
of practitioners. Direct medical costs were obtained from medical offices in the
Connecticut area with drug and herb cost based on 2002 published data. Several
sensitivity analyses were performed to test robustness of the results. The costeffectiveness of St. John's Wort was $1,788 per successful treatment compared to $2,043
for fluoxetine. Results were sensitive only to large fluctuations in cost of drug or herb
therapy. Thus, St. John's Wort is a viable option for patients with mild to moderate
depression.
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CHAPTER 1
INTRODUCTION

We are a nation focused on promoting healthy lifestyles, retarding the aging process, and
maintaining well-being. Over the last ten years or so, there has been a growing interest in
alternatives to traditional medicine such as natural products that claim to enhance health.
This is reflected in the rising sales of natural products, referred to as nutraceuticals, and
in total expenditures on integrative or alternative medicine. In 1997, Americans doled
out $27 billion in out-of-pocket expenses for alternative therapy, exceeding out-of-pocket
expenses on all physician services in the same year (Eisenburg, 1998). According to
Information Resources Incorporated, in 2002 over $591million was spent on herbal
supplements alone (Ferrier, 2002).

The marketing and advertising of these products seem to reflect consumers’ interest in a
more ‘holistic’ approach to health care (Astin, 1998). The gamut of botanical and
nutraceutical products available is truly extensive ranging from simple conventional food
supplements such as peppermint to plant derivatives of echinacea, ginkgo biloba, and
ginseng to animal products such as shark cartilage and fish oil. Though appeal in this
country seems novel, herbs have been used to treat illnesses for millennia (Cott, 1995).
Despite the development of many innovative synthetic medicines, of all prescription
drugs products, 25% are still derived from plants (Batz, 1998). For one specific product,
the consumer craze is most evident.
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ST. JOHN’S WORT
The herb Hypericum perforatum, also known as St. John's Wort, has received a great deal
of media attention over the past few years. A yellow flowering plant native to Europe
and Asia, Hypericum was brought in the late 18th Century to the Northeastern United
States where it has thrived naturally. It has been widely prescribed by German
physicians for a range of indications including depressive disorders, minor hemorrhages,
wound healing, and even bedwetting in children (Linde et al., 1996; Rao et al., 1991;
Vickery, 1981).

In 1994, over 66 million doses were prescribed for the treatment of depression in
Germany (De Smet and Nolen, 1996). German sales of Hypericum were $23 million in
1994 and grew to $66 million in 1996 (Nash, 1997). For one particular brand of
Hypericum, 200,000 prescriptions per month are filled in Germany compared to less than
30,000 for fluoxetine. In fact, prescriptions make up over 80% of the sales for
Hypericum transferring most of the cost of treatment to the health care system (Tyler,
1997). Across Europe, over $6 billion (United States dollars) were spent in 1998 on
products containing the extract (Bilia, 2002). Its popularity continues to grow in the
United States, though not quite as rapidly in the past year as questions of efficacy and
quality arise.

Uses of the herb date back to the ancient times of Hippocrates and Galen who wrote of
various medicinal properties such as the wound-healing, diuretic, and antiviral effects
Hypericum possesses. Among American herbalists, most notably John King, the
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documentation of Hypericum as an antidepressant, diuretic, and sedative continued
(King, 1866). Other countries that commonly use the herb for medicinal purposes
include Czechoslovakia, France, Poland, Romania, and Russia, which each list in their
respective pharmacopoeias (Hobbs, 1989; Reynolds, 1993). It is the most wellresearched and extensively used herbal antidepressant known (Bloomfield and
McWilliams, 1996). Media coverage has also been extensive with articles in popular
newspapers, magazines, and even television programs such as CNN and ABC’s 20/20
reporting the potential medical breakthrough of a safer, cheaper, and effective alternative
to prescription antidepressants.

With the side-effect profile being much more safe and mild compared to prescription
alternatives, Dr. Michael Jenike, editor of the Journal of Geriatric Psychiatry and
Neurology and professor at Harvard Medical School, reports Hypericum is a ‘particularly
attractive choice’ for elderly patients (Bloomfield and McWilliams, 1996). It is
noteworthy that individuals over the age of sixty-five are more likely than the general
population to suffer from a depressive disorder and much more vulnerable to side-effects
and drug interactions.

Private manufacturers of St. John's Wort have taken hold of the praises from the medical
community and have spread them like wildfire, adding some extras along the way.
Preparations of the herb can be found in combination with other ingredients such as
ephedra and cascara claiming to be a natural version of the once available prescription
combination, PhenFen. There is no evidence that the herb works as an appetite
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suppressant, but the advertising alone has been enough to spark a buy-in from the diet
industry. Over half of the dieters at all NutriSystem weight loss centers, representing
almost 250,000 people, reported taking St. John's Wort as a weight-loss supplement
(Associated Press, 1997).

Consumers too have accepted these claims with open arms. Sales of products containing
Hypericum have increased dramatically from $143,446 in 1996 to $29.4 million in 1997
according to Information Resources, Inc based in Chicago (Huff, 1998). By 1998, this
figure grew exponentially to over $5 billion (Brevoort, 1998). Certainly the boom in
advertising in addition to the increased availability of products has played a role in the
blossoming sales. However, most recently, sales have hit a plateau. Much of this has
been blamed on media attention questioning the effectiveness of the herb along with
disputes of the quality of many of the marketed products. Others point to the overall
decline in the economy blunting sales of any type of luxury item (Ferrier, 2002).

The once uninterested pharmaceutical giants quickly joined in the niche market,
manufacturing a variety of herbal supplements. GlaxoSmithKline markets St. John's
Wort along with a whole line of German herbals called Abtei. Following suit, Bayer
Pharmaceutical Consumer Product's division developed a line of vitamin supplements
that contain some of the most popular herbs such as Echinacea, Ginsing, Ginko, and St.
John's Wort. Other companies have attempted to gain prescription status for some of
these preparations and are currently seeking approval from the Food and Drug
Administration (FDA) (Wilke, 1997).
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An article in Health magazine (Benedict, 1998) reports that even people who aren’t
depressed are taking the herb. With the type of statements manufacturers are making, it’s
not surprising to hear this. Larry King claims that ‘clinically tested St. John's Wort keeps
him balanced emotionally’ in an advertisement on the radio for a combination product
containing Hypericum. Commonly referred to as the ‘Natural Prozac’, products claim all
the benefits with none of the adverse effects. It’s the new rage in curing what ails you.

So why are manufacturers allowed to make unsubstantiated claims that have not been
tested or may not have any medical evidence to back them up? The reason is due to the
relaxed regulations involved with the marketing of these products. Botanicals, such as
herbs, are considered dietary supplements and not drugs. Therefore, the marketing of
these products is not regulated with the same rigor as prescription or over-the-counter
drug products.

Herbs are not subject to FDA regulations but fall under the guidelines of the Diet Safety
Health and Education Act (DSHEA) of 1973. Under this act, a herbal product is
regulated as a food supplement and hence does not require proof of safety to be marketed.
However, the DSHEA does restrict manufacturers on the types of claims that may be
made regarding the product (Batz, 1998).

All claims that are made on the label must bear the words, “This statement has not been
evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent
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any disease.” Only ‘structure-function’ or ‘well-being’ claims can be made about the
product. In order for a product to be removed by the FDA, they must prove it to be
unsafe or prove a claim false (Batz, 1998). The FDA has been trying to develop current
good manufacturing practices (GMPs) for dietary supplement manufacturers since 1994
(Cooperman and Obermeyer, 2002). The standards are planned to be modeled after the
food industry rather than the drug manufacturers’ GMPs. As this is a difficult and timeconsuming process, it is expected to take several more years before it is implemented and
becomes law.

In other countries, such as Germany, there are finer, more well-established guidelines for
which products may be used as therapeutic treatments for illness. Again, these
regulations are not as rigorous as the FDA’s New Drug Application process in the United
States, but it does establish criteria for which the product may be used. The German
Commission E is a division of the German regulating agency similar to the United States
FDA. They have developed a monograph system that evaluates the use of herbal
products for medicinal use. Absolute proof of safety is required for approval and relative
proof of efficacy through clinical trials or historical use (Batz, 1998).

Commission E is continually developing more monographs. St. John's Wort was one of
the first established. Having the monograph system as a therapeutic guide, physicians in
Germany are very knowledgeable and confident about prescribing herbs for chronic
conditions. In 1999, the United States Pharmacopeia (USP) published a monograph and
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established recommended potency of specific constituents based on High Pressure Liquid
Chromotography analysis (USP, 1999).

Whether this growth in alternative medicine has been spurred by a general
disenchantment with traditional therapies or simply a desire to try a more natural, holistic
approach to health care, it is a reflection of the desires and interests of consumers. The
dearth of information available for many of these alternatives emphasizes the need to
cautiously scrutinize and judge the potential of these products as viable alternatives. The
public and healthcare community needs an unbiased approach to be taken to accurately
assess the role these botanicals have in health care. Cost-effectiveness analyses can serve
to do this along with providing information to businesses wishing to meet the needs of
their customers such as Health Maintenance Organizations (HMO) and other third party
payers of healthcare.

In the midst of all the media hype, there does seem to be a legitimate use of the herb
called St. John's Wort. The documented use in Germany, more recent published
American trials, and expert opinion from physicians in the United States suggests great
potential of this herb for the treatment of mild to moderate depression. Since the cost is
about one-tenth to one-fifth that of its prescription comparisons, savings to the patient
and the health care system could be tremendous.

However, mere acquisition cost is not enough to comprehensively assess the impact a
new treatment for depression can have on society and the health care system in general.
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Therefore, this study shall focus on the relative cost-effectiveness of St. John's Wort
versus fluoxetine, one of many prescriptive comparators, in the treatment of mild to
moderate depression. This type of analysis can provide much more information to
patients, providers and payers of health care than clinical trials measuring efficacy alone.
Nonetheless, many factors must be considered to construct a model representative of all
costs and consequences.

One must understand the complexity of the disorder and the extent to which it affects
individuals in this country. Furthermore, treatment should be assessed in relative terms.
It makes sense to compare the potential therapy with a gold standard, such as one of the
selective seratonin reuptake inhibitors (SSRIs) currently available. The following two
sections shall provide the information needed to justify the comparison of St. John's Wort
to fluoxetine in the treatment of mild to moderate depression.

DEPRESSION
Approximately 6.7 million women (6.5%) and 3.2 million men (3.3%) aged 18 years and
over have a depressive disorder in the United States in a given year (Narrow, 1998). Of
course the true prevalence of depression is not known partly due to the characteristics and
social stigma surrounding the condition. Most cases are not diagnosed by psychiatrists
but by general practitioners, making it one of the most frequently presented conditions in
the primary care setting. Approximately 25% of patients seen in the primary care setting
have some form of depression (Henry and Rivas, 1997). Paradoxically, primary care and
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other non-psychiatric practitioners often under-diagnose and under-treat depressive
symptoms despite their common occurrence.

Diagnostic criteria according to the Diagnostic and Statistical Manual (DSM-IV) for a
major depressive episode include five or more of the following symptoms lasting at least
two weeks or more with depressed mood or anhedonia being one of the five symptoms
(DSM-IV, 1997):
•
•
•
•
•
•
•
•
•

Depressed Mood
Loss of interest or pleasure in usual activities (anhedonia)
Significant weight loss or gain
Insomnia or hypersomnia
Psychomotor agitation and retardation
Fatigue
Feelings of worthlessness or guilt
Diminished ability to think or concentrate
Recurrent thoughts of death or suicidal ideation

Along with eliciting the appropriate signs, symptoms, and history of illness, knowledge
of associated risk factors is a key determinant in the detection and diagnosis of
depression. The primary risk factors for depression are (Depression Guideline Panel,
1993):
•
•
•
•
•
•
•
•
•
•

Prior episodes of depression
Family history of depressive disorder
Prior suicide attempts
Female gender
Age of onset under 40
Postpartum period
Medical co-morbidity
Lack of social support
Stressful life event
Current alcohol or substance abuse

9

As stated above, a prior depressive episode represents a significant risk factor for
recurrence of depression. In fact, an individual diagnosed with depression has a 50%
chance of suffering a subsequent episode. The rates increase dramatically with the
number of reported episodes, up to 90% with three or more episodes (National Institute
of Mental Health Consensus Development Conference, 1985). Relapse is also highly
associated with medication adherence. Individuals treated with adequate doses of an
antidepressant that experience remission of symptoms are more likely to remain in
remission if maintenance therapy is continued for a period of at least six months (Henry
and Rivas, 1997).

The more the complexity of this disorder is understood, the more apparent becomes the
debilitating nature of depression. Individuals frequently somaticise symptoms causing
chronic pain, gastrointestinal disturbances such as peptic ulcers, and a host of other
conditions. Hospital costs are usually 35% greater and visits are twice as long for
depressed patients with physical illnesses compared to patients of similar severity without
depression (Henry and Rivas, 1997).

Due to the nature of depression combined with the associated stigma, frequently,
depressed persons withdraw from society and are unable to engage in daily activities
including going to work. This represents another significant cost to the individual
through lost wages as well as to society through a loss of productivity. Adding another
cloud to the dismal picture already painted is the high rate of suicide accompanying
major depression with a ten to 15% mortality rate (Henry and Rivas, 1997). According to
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a study conducted by the World Health Organization along with Harvard University, the
fourth leading cause of disability worldwide can be attributed to major depression
(Murray, 1996).

Pressures to decrease medical costs have put a tremendous burden on the health care
system and mental health services in particular. Fewer HMO’s are willing to pay for
specialized psychiatric treatment, and many plans carve out mental health from general
health benefits. With depression being one of the top ten reasons an individual consults a
family physician, primary care practitioners are handed the challenge of providing quality
care at an affordable cost. The most widely prescribed classes of antidepressants in the
United States are the SSRIs. One of the most commonly prescribed drugs in this class is
fluoxetine (Prozac).

Annual costs of depression in the United States were estimated at $43.7 billion in 1990
including treatment, disability, and loss of productivity (Colchamiro, 1998). The costs in
total are greater than that of ulcers, diabetes, arthritis, or hypertension (Tyler, 1997).
Pharmacotherapy can be quite costly especially when newer agents such as the SSRIs or
combination seratonin/norepinephrine re-uptake inhibitors (SNRIs) are used. Costs for
these therapies can run as high as seven dollars per day. Less expensive alternatives do
exist but sometimes at the expense of bothersome and toxic effects. Also, these
compounds may not be appropriate for all types of depression.

11

FLUOXETINE
Since it’s introduction over 10 years ago, fluoxetine has been available to psychiatrists,
primary care physicians, and other non-psychiatric physicians as effective
phamacotherapy for patients with depression. It’s arrival undoubtedly made its mark in
the prescribing arena. Evidence of this comes from impressive standings as the number
one prescribed antidepressant and the second top selling drug in the country when
considering all prescription drugs in 1998. Manufacturer Eli Lilly & Co. boasts sales of
greater than $2 billion per year (Tyler, 1997).

Its popularity among prescribers is due to a number of clinical reasons. Tricyclic
antidepressants (TCAs), prior to fluoxetine’s market approval, were the cornerstone of
antidepressant therapy for decades. Fluoxetine presented an incredible advantage over
this class of compounds offering a wide therapeutic range with little toxicity in overdose.
The side-effect profile is more benign and fewer patients have been shown to discontinue
therapy compared to TCAs (Stokes and Holtz, 1997). In light of this, fluoxetine is
thought to enhance medication adherence during maintenance therapy and thus, improve
response and decrease chance of relapse.

One advantage of fluoxetine over other SSRIs is the relatively long half-life it has (four
to six days with chronic administration). This enables patients to have a convenient once
a day dosing schedule and the titration that is necessary with many of the TCAs is not a
factor for patients beginning therapy with fluoxetine. A new once-weekly formulation
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was marketed in October, 2002, potentially increasing adherence and convenience even
more.

As far as acquisition cost of the drug, Prozac was one of the most expensive
antidepressants on the market. However, the patent expired in October, 2001, and
generic fluoxetine entered the market. Its cost is about one-third the cost of the brand.
Even with the generic now available, the cost of treatment is still more expensive than
that of St. John’s Wort. Hence the question still remains. Is fluoxetine, representing the
class of SSRIs, the most cost-effective drug to treat mild to moderate depression?

STATEMENT OF THE PROBLEM

With the rising costs of healthcare, it is becoming imperative to use treatments that have
proven value. One way to determine this value is through cost-effectiveness analyses.
Depression, a costly disorder physically, financially, and emotionally, impacts our society
greatly. With 9.5% of the population age 18 and older being affected in a given year,
there is a need for effective treatments that are well tolerated (Regier, 1993).
Determining the relative cost-effectiveness of different therapies for depression is
important due to the prevalence and high costs associated with its treatment.

Selective seratonin reuptake inhibitors such as fluoxetine have made substantial
contributions to the existing antidepressant treatments by offering superior safety,
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convenient dosing, and in some ways a more tolerable side-effect profile. Unfortunately,
the cost of these drugs is very high, and expense of treatment can be a major hurdle for
all involved in the healthcare system. If herbal therapies were as safe and effective as
fluoxetine for the treatment of depression, but were less expensive, patients could be
treated more efficiently or cost-effectively.

Global and economic pressures have created a renewed interest in natural product
research that has provided us with extensive documentation and clinical information on
certain herbs. Clinical trials conducted on St. John's Wort document its efficacy in the
treatment of mild to moderately severe depression, and associated side-effects are almost
nonexistent. The cost of the herb is about one-fifth that of the brand Prozac. However, a
direct and comprehensive comparison of the cost-effectiveness of fluoxetine with St.
John's Wort has not been conducted. Such a comparison would be useful in guiding
formulary decisions and treatment algorithms for depression.

GOALS AND OBJECTIVES
The goal of this study is to determine the cost-effectiveness (cost per successfully treated
patient) of St. John's Wort compared to fluoxetine in the treatment of mild to moderate
depression for a treatment period of one year. The perspective of the study shall be the
third party payer or managed care point of view. This goal will be accomplished by the
following objectives:
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Objective A. Calculate the expected cost associated with the treatment of mild to
moderate depression using fluoxetine at the initial dose of 20 mg once a
day.

Objective B. Calculate the expected cost associated with the treatment of mild to
moderate depression using St. John's Wort at the initial dose of 300 mg
three times a day.

Objective C. Assess the overall cost per successfully treated patient (cost-effective
ratio) who responds to St. John's Wort.

Objective D. Assess the overall cost per successfully treated patient (cost-effective
ratio) who responds to fluoxetine.

Objective E. Assess the incremental cost-effectiveness ratio for St. John's Wort
compared to fluoxetine.

Objective F. Assess the robustness of the findings by conducting sensitivity analyses.

SIGNIFICANCE OF THE STUDY
St. John's Wort has been used to treat depression, which is a very prevalent, disabling,
and costly disorder in this country. The current standard treatment for patients with mild
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to moderate depression is costly and can cause troublesome side-effects that may
decrease quality of life and may influence discontinuation of the medication. It is
worthwhile to compare the relative effectiveness and cost of this commonly used herbal
treatment to fluoxetine, a drug from the class most often used for depression today. It
may represent a new effective treatment choice for patients suffering from this disorder
and concurrently decrease the costs of care for this sizable population.

Improvements in pharmacotherapy have been incremental over the last decade. Selected
populations may benefit extensively from the safety and tolerability of St. John's Wort.
Side-effects such as anxiety and sexual dysfunction may no longer plague those trying to
fight the battle of depression. Additionally, those with no health insurance may no longer
have the hurdle of cost of therapy to overcome.

More informed decisions can be made in the light of the information this study can
provide. The model can serve to integrate clinical data and expert opinion that is
currently available until more definitive studies are available. Managed care
organizations can objectively assess the potential of St. John's Wort as a formulary drug
and its potential impact on the effectiveness and costs of treating patients with
depression.
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CHAPTER 2
LITERATURE REVIEW
INTRODUCTION
The literature that focuses on depression and issues concerning pharmacologic treatment
is quite extensive. With the substantial impact this disease imposes upon the world, such
interest is no surprise. Depression has been listed as the number one cause of disability
in the world (Murray, 1996). Much has been learned about the epidemiology of
depression such as risk factors, diagnostic criteria, prevalence, treatment protocols, and
relapse rates. The vast gamut of research in this area has aided in the development of
clinical treatment guidelines established by the Agency for Healthcare Research and
Quality (formerly the Agency for Healthcare Policy and Research (AHCPR, 1999).
Progressive research has also lead to the discovery of more compounds possessing
antidepressant properties.

With the market availability of these new antidepressants, controversies arise over the
actual benefit in treating the disorder. Given that new drugs added to the list of
prescriptive antidepressants have a much higher acquisition cost relative to their older
counterparts, budget constraints force policy makers to ask questions about how and
when to use these therapies. Concerns such as these have been addressed in the
literature. Many researchers have tried to evaluate the impact that choice of drug
treatment has on total cost of care by utilizing techniques of pharmacoeconomics.
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In general, pharmacoeconomic evaluations include any study that examines costs and
consequences of alternatives (Bootman, 1996). Examples of these are cost-benefit, costutility, cost-minimization, and cost-effective analyses. A variety of approaches can be
used to conduct studies such as these. A method commonly used since the early 1970s is
economic modeling (Lusted, 1971). There are three basic modeling approaches that a
researcher can take. These are epidemiological, Markov, and decision analysis modeling
(Drummond, 1997). Some basic information on each of these approaches follows with a
more in-depth discussion of decision analysis presented in Chapter 3.

ECONOMIC MODELING TECHNIQUES
Epidemiological models are commonly used when intermediate outcomes are measured
as a proxy for final outcomes (Drummond, 1997). Often times a relationship must be
established between the intermediate and final outcomes in order for a meaningful
economic evaluation to be done. Biological measures such as blood pressure or serum
cholesterol are often used as indicators or predictors of coronary artery disease (CAD) in
clinical trials. By using epidemiological data combined with modeling techniques, risk
rates can be established to link the biological marker to the final outcome of CAD.

In cases where the disease or treatment is characterized by chronically recurrent events or
a number of different health states, an alternative approach is Markov modeling. Markov
models incorporate probabilities of transition between different health states for each
cycle specified by the model (Drummond, 1997). The cycle has a defined time frame,
and a defined number of times it is repeated. The cycle length in the model often differs
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from the evaluation length in the clinical study where probability estimates are derived.
This necessitates the calculation of hazard rates to estimate transition probabilities.

The third method, decision analysis modeling, has been used extensively in health care
(Weinstein and Fineberg, 1980). It involves a process of delineating all possible costs
and outcomes of two or more alternatives over a specified time period by way of a
decision tree. The tree enables visualization of different choices and the associated
chances (uncertainty) represented in the clinical scenario and calculates the optimal
alternative under the chosen assumptions (Lawler, 1995).

In order to construct such a model, certain elements must be addressed. Perspective of
the study, length of treatment, and model assumptions must be clearly described. In
order to analyze the model, effectiveness, safety, and cost data for each therapeutic
alternative must be evaluated. Additionally, the classification of major depression and
associated treatment practice patterns must be taken into consideration. The following
sections discuss these issues required to conduct this economic evaluation.

MAJOR DEPRESSIVE DISORDER
Major Depressive Disorder (MDD) is a growing health concern in the United States with
approximately 6 to 8% of all primary care patients suffering from the disorder (AHCPR,
1999). The economic impact caused by social and physical dysfunction has been
estimated to be greater than that of many chronic medical conditions such as diabetes and
heart disease. In 1990, total cost of MDD was $43.7 billion according to a study
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examining the financial burden due to loss of productivity and absenteeism, suicides, and
treatment and rehabilitation (Greenberg, 1993).

Due to a number of factors indigenous to the disorder, MDD has gone unrecognized and
hence untreated in many individuals. In many cases, depression is mistaken for anxiety;
in fact, only about half the patients diagnosed as having a depressive or an anxiety
disorder exhibit relatively pure syndromes of one type or the other (Brown, 1997).
Additionally, although they are separate diagnostic categories, other psychiatric medical
disorders may exist with depression such as bipolar illness or psychoses. In light of this,
efforts are being made to improve the diagnostic acuity of physicians in primary care
where more often than in any other setting, the associated symptoms are presented (Bilia,
2002).

The diagnostic criteria for MDD include five or more of the following symptoms to be
present most of the day, nearly daily, for a period of two weeks or more. At least one of
the first two listed symptoms must be present (Williams, 2000):

1.
2.
3.
4.
5.
6.
7.
8.
9.

Depressed Mood.
Loss of interest or pleasure in usual activities (anhedonia).
Significant weight loss or gain.
Insomnia or hypersomnia.
Psychomotor agitation and retardation.
Fatigue.
Feelings of worthlessness or guilt.
Diminished ability to think or concentrate.
Recurrent thoughts of death or suicidal ideation.
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Another phenomenon existing with this disorder is the alarming rate of relapse. An
individual diagnosed with depression has a 50% chance of suffering a subsequent
episode. The rate increases drastically with the number of reported episodes, up to a 90%
chance of relapse with three or more episodes (NIH Consensus Development Conference,
1991) but can be minimized with continued use of an effective antidepressant. This
verity has lead to the recommendation of continuing antidepressant therapy for at least 16
weeks beyond initial recovery for a total of six to 12 months of treatment (Williams,
2000).

Selecting the antidepressant, once a diagnosis of MDD has been made is based on a
number of factors. Issues involving safety and effectiveness of the drug are of primary
concern in the decision making process. Before there is any established use of a drug,
this information predominantly comes from published randomized clinical trials where
efficacy can be measured by severity rating scales.

A diagnosis of depression categorizes the medical illness but does not delineate the level
of severity. There are three main levels under which depression may fall: severe,
moderate, and mild depression. About 75% of all depressive illnesses are of mild to
moderate severity (Muller and Voltz, 1996). A number of instruments are available to
assess the severity of depression, which is essential when investigating efficacy of
treatment modalities.
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DEPRESSION RATING SCALES
The Hamilton Depression Rating Scale (HAMD) is an observer-rated depression scale
created specifically for the purpose of assessing severity level. It was developed in 1960
by Max Hamilton. The author intended its use only for patients already diagnosed with
major depressive disorder.

There are several versions available today, but the original is a 21-item scale. A 31, 25,
24 and 17-item scale have been reported with the original and abridged versions being the
more commonly used. A fairly wide range of symptoms is covered by the original
version including the core symptoms of depression, hypochondriasis, loss of insight,
obsessive-compulsive features, anxiety, and psychosocial impairment. Hamilton stated
the reason for such a comprehensive coverage of symptoms was due to the fact that these
were the features that usually presented in patients diagnosed with depression (Snaith,
1996).

Typically, an improvement in a patient’s severity or a response to treatment is defined as
a 50% decrease in baseline score or an endpoint score < 10. Through various studies
conducted on non-clinical samples, absolute HAMD scores between six and eight are
considered to be the normal range for healthy populations (Fawcett, 1997). Therefore,
total remission of depressive symptoms or optimal response to therapy can be determined
based on this range of scores.

22

Currently, the HAMD is the most prevalent scale used in psychiatric research for the
severity of depression assessment (Snaith, 1996). However, there are a number of other
scales that have been used to evaluate therapeutic efficacy. Some examples of these
include the Bech-Rafaelsen Melancholia Scale (BRMS), the Montgomery-Asberg
Depression Rating Scale (MADRS), the Depression Anxiety and Stress Scale (DASS),
the Beck Depression Inventory (BDI) and the Clinical Global Impressions index (CGI).

The BRMS is a self-rated scale used to assess severity of symptoms. Unlike the HAMD,
it can also be used to diagnose depression. It consists of eleven items with five levels of
scoring. While the HAMD covers a broad range of emotional symptoms, the BRMS
covers all core symptoms of depression and only a limited number of questions are
devoted to anxiety. Similar to the HAMD, the BRMS has demonstrated excellent
reliability measures and valid interpretations of severity assessment in depressed patients
(Maier, 1988).

The MADRS was initially devised to be more sensitive toward change in severity during
treatment than the HAMD. It is also a self-report instrument. It contains ten items and
seven levels for the scoring of those items. Additionally, it has a much narrower focus
than the previous two scales discussed. There is sufficient evidence demonstrating its
reliability and validity for the purpose of depression severity rating (Bech, 1986).

The Depression Anxiety and Stress Scale (DASS) consists of 42 negative emotional
symptoms that is self-rated. This instrument differs from the others specifically based on
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the fact that three distinct domains are tapped compare to the more common two domain
structure of depression and anxiety. The factors contained in the depression scale relate
to a loss of self-esteem and incentive and are associated with a low perceived probability
of attaining life goals of significance for the individual (Lovibond, 1995).

The BDI is most often used for psychotherapy studies. It is a standardized scale rated by
the patient on functional and emotional outcomes. Studies have shown that scores
obtained from this scale correlate with those obtained by the HAMD.

The CGI is an observer rated instrument that has three indices of measurement. Not only
does this instrument assess severity of illness, but it also assesses global improvement
and efficacy of therapy. The CGI is commonly used to represent global improvement
and is used in combination with one or more of the aforementioned scales. Results are
presented as nominal data such as “improved” or “much improved” (APA, 2000).

Each of these scales as well as numerous others not mentioned here allows for the
assessment of severity of symptoms in patients diagnosed with depression. Some scales
are able to tap into different domains of the disorder better than others. However, most of
the studies in which these scales were used did a good job of assessing therapeutic
response rates as evidenced by similar findings for effectiveness rates.

When similar results are obtained by multiple scales that assess severity, it becomes
apparent that the data is more robust than simply using results of one scale. It is
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frequently necessary to combine results of studies that have used different instruments to
assess response to therapy. Meta-analysis can be a useful tool to capitalize on external
validity, which is advantageous for studies such as cost-effective analyses whose results
tend to have policy or program implications (Luce and Simpson, 1995).

PHARMACOTHERAPY FOR MAJOR DEPRESSION
Pharmacotherapy is the only proven method for treating all levels of severity of MDD
(Stokes and Holtz, 1997). There are a number of options available on the market today.
The first compounds discovered make up the class referred to as tricyclic antidepressants
(TCAs). The drugs falling under this heading are extensive including imipramine,
amitriptyline, and desipramine. These drugs have been a mainstay in depression therapy.
With over forty years of clinical use, their effectiveness in treating depressive symptoms
is well documented.

The empirical research on efficacy does not favor any particular TCA over another in
depressed populations. Approximately 50 to 80% of depressed patients have responded
to tricyclic therapy, with the most extensive documentation on amitriptyline and
imipramine (Einarson, 1995; Depression Guideline Panel, 1993). The mechanisms by
which these drugs exert their effect cause a host of troublesome side-effects and have
long been a barrier to symptom control. Compliance problems occur in 15 to 20% of
patients on TCA regimens. Anticholinergic effects such as dry mouth and sedation along
with potentially fatal cardiotoxic properties have precipitated the search for better
tolerated, safer alternatives.
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This search lead to the discovery of a class of compounds commonly referred to as
selective seratonin reuptake inhibitors (SSRIs). To date, there are six marketed
compounds in this category: fluoxetine (Prozac), paroxetine (Paxil), sertraline
(Zoloft), fluvoxamine (Luvox), citalopram (Celexa), and escitalopram (Lexapro).
There are only diminutive differences among them, manifested mainly in the side-effect
profile, half-life, and drug interactions associated with each.

The side-effect profile culled from clinical trials as well as real-world experience is rather
favorable compared to TCAs. Great improvements were made with the lack of
anticholinergic effects; however, somewhat bothersome reactions still remain. The
majority of side-effects seem to appear and subside within the first few weeks of therapy.
The most commonly reported adverse reactions with fluoxetine are nausea (23%),
headache (21%), insomnia (20%), anxiety (13%), nervousness (13%), and somnolence
(13%). Sertraline is likely to cause more nausea ( 27%), while paroxetine is more likely
to be associated with lethargy (24%) than other SSRIs as reported in trials and clinical
practice (PDR, 2002).

Sexual dysfunction is another effect common to all SSRIs. Unlike the other side-effects
of headache, nausea, and dizziness that tend to dissipate within the first few weeks,
sexual dysfunction can occur and persist late into therapy (Stokes and Holtz, 1997). For
patients intolerant to this effect, other effective alternatives exist such as the heterocyclic
antidepressant buproprion (Wellbutrin), which may actually increase sexual drive.
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Another salient difference among the SSRIs is the elimination half-life. Fluoxetine
possess the longest half-life four to six days with chronic administration relative to all
other antidepressants (Stokes and Holtz, 1997). This enables patients to have a
convenient once-a-day or even every other day dosing schedule. In February 2001, a
once-a-week formulation of Prozac was approved for patients already maintained on a
stable dose of fluoxetine.

The titration that is necessary with many of the TCAs is not a factor for patients
beginning therapy with fluoxetine. Consequently, patients can remain on the initial
therapy dose throughout the treatment phases. However, because of this, if
discontinuation is warranted, the wash-out phase for switching antidepressants is
recommended to be much longer (four to five weeks) for fluoxetine than the other SSRIs.
However, this recommendation is rarely followed in clinical practice.

Another class of compounds, similar in action to the SSRIs, exists as a treatment option
for major depression. Combining the inhibition of serotonin with the inhibition of
norepinephrine, a class of drugs known as SNRIs (serotonin-norepinephrine reuptake
inhibitors) were produced. Venlafaxine (Effexor) and nefazodone (Serzone) are two
compounds currently available. Significant efficacy over placebo has been documented
for both drugs (Moller and Voltz, 1996; Rickels, 1994).
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Side-effects for these drugs are also more tolerable compared to TCAs. The most
common adverse effects for venlafaxine are nausea, somnolence, dry mouth, dizziness,
and constipation. Also, it is associated with blood pressure elevation. This phenomenon
occurs in about 3% of patients (Moller and Voltz, 1996). Nefazodone has similar sideeffects with less initial anxiety and sexual dysfunction than SSRIs, especially fluoxetine
(Revicki et al., 1997).

COMPARATIVE EFFICACY-FLUOXETINE
In examining the comparative efficacy of fluoxetine and other antidepressants, relatively
short-term studies reveal fluoxetine to be equally efficacious and distinctly more tolerable
than TCAs (Nielsen et al., 1993; Workman and Short, 1993). These studies also support
the claim that fluoxetine use is associated with lower rates of discontinuation than the
TCAs.

Studies comparing fluoxetine with the other SSRIs in addition to other agents such as the
SNRIs are also abundant. Double-blinded multicenter trials have demonstrated similar
efficacy and comparable side-effects profiles for all of the SSRIs and SNRIs. Moderately
to severely depressed outpatients assessed by HAMD improved similarly with fluoxetine
or sertraline with at least a 55% responder rate in each group (Aguglia et al., 1993). The
occurrence of adverse reactions also was reported at similar rates, but the sertraline group
had fewer drop-outs due to side-effects. This result may be due to the pre-treatment
differences between groups that were observed.
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No significant differences were reported in a study of outpatients scoring at least 18 on
the HAMD randomized to receive either fluoxetine (20 to 60 mg daily) or paroxetine (20
to 40 mg daily) (Gagiano, 1993). More than 60% of patients had a 50% reduction in
HAMD scores in both groups. CGI scores also confirmed a greater than 60% response
rate. Additionally, treatments were well tolerated with only three withdraws in each
group out of 90 due to adverse effects.

A double-blinded study comparing fluoxetine to fluvoxamine assessed 93 outpatients
with major depression (Rapaport et al., 1996). According to HAMD scores, no
significant differences were found in treatment response after seven weeks of therapy.
Both groups reported mild side-effects and only two patients in each group withdrew
because of adverse events.

Comparisons of fluoxetine to citalopram have also been conducted (Patris, 1996). A
double-blinded multi-center trial evaluating 314 depressed outpatients found no
significant differences in efficacy or tolerability. Response was assessed according to a
50% reduction in baseline MADRS scores. Fluoxetine-treated patients had a 76%
response rate, and citalopram-treated patients had a 78% response rate. CGI results
yielded over 80% of both groups reporting “much improved” or “very much improved”.
Ten patients withdrew from citalopram treatment and four from fluoxetine treatment.

A 12 week double-blinded randomized control trial compared fluoxetine with venlafaxine
(Tylee and Bowden and Reynolds, 1996). Three hundred forty-one depressed outpatients

29

were assessed by MADRS, HAMD, and CGI scores. Sixty-eight percent of fluoxetine
patients and 63% of venlafaxine-treated patients responded to therapy according to
HAMD scores. Similar results were obtained by the other scale scores with no
significant differences detected between treatment groups. Similar results were reported
in a study comparing fluoxetine to nefazodone (Rioux et al., 1996).

A recent publication in the Journal of the American Medical Association reported that
there were no differences in efficacy of three leading SSRIs. (Kroenke, 2001). A total of
573 adults diagnosed with depression by their primary care physicians were randomized
to receive either fluoxetine, sertraline, or paroxetine and were followed for 9 months.
The primary outcome measure was change in the Medical Outcomes 36-item Short-Form
Health Survey (SF-36) Mental Component Summary score. There were no statistical
differences among the three treatment groups over the nine-month period in terms of
effectiveness, discontinuation, or adverse effects.

There is clear consensus that fluoxetine is effective for the treatment of major depressive
disorders. However, there is not a clear consensus on how effective it is. A metaanalysis of 26 trials testing fluoxetine in adult outpatients reported a mean response rate
of 46.6% (Depression Guideline Panel, 1993). While another study reported an average
response rate of 64.6% for outpatients treated with fluoxetine (Einarson, 1995). Another
more recent analysis comparing the newer agents against each other, including fluoxetine
reported no significant differences with an average response rate of 53% (Williams, et al.,
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2000). However, most of these patients were recruited from inpatient settings and
therefore, probably more severely ill.

As previously mentioned, scores obtained by HAMD as well as other scales are
traditionally accepted as a measure of severity of depression. The aforementioned studies
mainly evaluated moderate to severely depressed patients as indicated by the initial
HAMD score. Documentation of efficacy for patients with more mild forms of the
disorder is also important.

In 1993, a study was published addressing the issue of response to fluoxetine based on
severity of depression (Pande and Sayler, 1993). The authors pooled results of 19
double-blinded randomized clinical trials involving the comparison of fluoxetine with
either placebo or a TCA (amitriptyline, imipramine, desipramine, doxepin, or
nortriptyline) to yield a total of 3,183 patients with major depressive disorder.

Patients were stratified into three severity levels (mild, moderate, and severe depression)
based on total HAMD scores at baseline. The results were then re-analyzed to yield
response and remission rates for each stratum. No significant differences in efficacy
were found between groups based on severity of illness.

In all groups, fluoxetine was more effective than placebo with higher remission rates and
as effective as TCAs with similar remission rates. However, remission rates were highest
in the mild depression subgroup and lowest in the severe depression subgroup, as would
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be expected. The average response rate for patients with mild to moderate depression
was 66.5% for the fluoxetine group. This study successfully illustrated the effectiveness
of fluoxetine for all severity levels of MDD.

A review of newer antidepressant therapies including fluoxetine used to treat non-major
depression or dysthymia corroborates this. Patients randomly assigned to receive an
SSRI had a response rate of 59% compared to 37% for the placebo group. All patients
were treated in an outpatient setting. Even in mild to moderate depression, fluoxetine, as
well as the other antidepressants, was demonstrated to be effective (Williams et al, 2000).

Data thus far regarding the use of fluoxetine to treat depressive disorders has seemingly
justified its popularity among practitioners, making it a good representative for all SSRIs.
Patients as well as practitioners have reaped the benefits of increased tolerability, equal
efficacy, and convenient dosing compared to other antidepressants. The addition of the
drug to the previously available arsenal of agents has made substantial strides in
management of mental illnesses in a number of areas including the treatment of mild to
moderate depression.

However, another therapy does exist that has been used extensively in Germany. Falling
under a more unconventional approach, this herb has received much attention in the
United States over the past few years. The herbal remedy being referred to is Hypericum
perforatum, better known as St. John's Wort.
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HERBAL THERAPY FOR MAJOR DEPRESSION
St. John's Wort is a flowering plant that contains at least ten constituents or groups of
components that may contribute to its pharmacological effects. The two primary classes
of constituents are naphthodianthrones (hypericin and pseudohypericin) and flavonoids
(hyperforin and adhyperforin). Most researchers have focused their attention on the
effects of hypericin and hyperforin as possessing antidepressant effects. However, there
are numerous compounds with documented biological activity.

Activity and potency may vary depending on the method of extraction and the percentage
of standardized constituents. Most commercially available products are standardized
based on a hypericin content of 0.3%. The USP recommends that all preparations are
standardized to no less than 0.2% hypericin/pseudohypericin or no less than 3%
hyperforin based on analysis by high performance liquid chromatography (USP, 1999).
Additionally, a specific extraction method has been identified that offers a high yield of
hypericins and hyperforins (Poutaraud, 2001). Given the contribution of these critical
compounds to the overall effectiveness of the extract, it is imperative that strict controls
are employed during manufacturing.

The exact antidepressant mechanism of action is unclear at present. However, studies
have demonstrated the extract to have multiple mechanisms of action in vitro. Once
thought to be a monoamine oxidase (MAO) inhibitor, it has now been shown to have very
little affinity for these receptors. Hydroethanolic extracts exhibit activity at gammaaminobutyric acid (GABA) receptors but only weakly inhibit MAO. Hydromethanolic
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extracts act similarly to reserpine by releasing stored seratonin (5HT) thereby increasing
cytoplasmic concentrations causing reuptake inhibition in the synapse. These extracts
also inhibit norepinephrine (NE) and dopamine (DA) (Muller, 1997).

Hypericin alone has been shown to inhibit the metabolism of DA. It has affinity at
GABA type A and 5HT receptors but no significant affinity at adenosine, adrenergic,
central benzodiazepine, or opioid receptors. Relatively low affinity was shown for Nmethyl-D-aspartate and MAO type A receptors. Hyperforin also inhibits neuronal uptake
of DA, NE, 5HT, and GABA, whereas MAO inhibition is insignificant (Bilia, 2002).
The combined effects on the various neurotransmitters most likely explain its clinical
activity, rather than one simple mechanism.

Although a multitude of reports and studies suggest that the extract is well tolerated and
generally safe to use, there is evidence that many of the herb's constituents interact with
other drugs, mainly those metabolized by the hepatic Cytochrome P450 enzyme system.
St. John's Wort is a known inducer of many of the isoenzymes such as 3A4, 2C9, and
2D6 as well as P-glycoprotein expression (Ernst, 1999). Consequently, it can interact
with a number of different drugs. Most reports involve decreases in plasma levels of the
drugs, thereby reducing therapeutic effectiveness. Interactions can be quite severe such
as with cyclosporine. Acute rejection of solid organ transplants have been reported
(Turton-Weeks et. al., 2001). It is therefore recommended to avoid concomitant use of
the herb and any drug affected by these isoenzymes, such as anticoagulants (warfarin),
antiretrovirals, and oral contraceptives.
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Though not quite as extensive as its prescription counterpart, the research published on
St. John's Wort is evident. In the early 1990's, European studies supplied most of the
information regarding efficacy, tolerability, and safety of certain extracts for the
treatment of mild to moderate depression. Today, published US trials on St. John’s Wort
document its use in the treatment of depression as well as continued anecdotal support.

In ABC’s investigative report, medical editor, Dr. Timothy Johnson interviews Dr.
Harold Bloomfield. Dr. Bloomfield is a Yale-educated psychiatrist and author of the
best-seller “How To Heal Depression”. He became interested in the herb’s potential as
an antidepressant and started reading and studying its effects before ultimately using it in
clinical practice. The results he has seen with his patients prompted him to write another
book titled “Hypericum and Depression” where he praises the ability of this herb to
effectively treat mild to moderate depression with mild or no side-effects (Bloomfield
and McWilliams, 1996).

So impressed with the results he has seen from the hundreds of patients for whom he
prescribed the herb, Dr. Bloomfield emphasizes the importance of St. John's Wort by
stating in his book and on national television that it should be the drug of choice for mild
to moderately severe depression. He predicts that it will soon outsell all other
antidepressants and become the leading therapy choice despite the massive marketing
campaigns of pharmaceutical companies. That will be no small feat considering
fluoxetine’s sales of $2 billion per year in 1995 alone (Murray, 1995).
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Many other experts in the field seem to share his enthusiasm. A psychologist at the
National Institute for Health, Jane Steinberg agrees that there is good evidence of the
herb’s effectiveness (Benedict, 1998). Author of “St. John's Wort: Nature’s Blues
Buster”, Dr. Hyla Cass has switched many of her patients from synthetic antidepressants
to the herb and states that it is “unquestionably superior” to conventional therapy in the
treatment of mild to moderate depression (Colchamiro, 1998).

Countries well versed in using phytomedicinals have provided excellent documentation
and a wealth of information on clinical experience. Over thirty controlled studies have
been conducted on Hypericum to demonstrate its effect in patients with depressive
disorders. The British Medical Journal published a meta-analysis of 23 randomized
clinical trials in which the authors found sufficient evidence to claim Hypericum’s
superiority over placebo in the treatment of mild to moderate depressive disorders (Linde
et al., 1996). Dr. Cynthia Mulrow, one of the co-authors of the analysis, now
recommends the herb as an alternative to her patients diagnosed with depression (Huff,
1998). The extract has been studied in over 1,700 individuals with most trials using the
German extract LI 160, although several other brands have also been tested.

In a placebo-controlled, double blind study conducted by Harrer and Sommer (1994), 105
mildly depressed patients were given 300 mg of the extract LI 160 three times a day for
four weeks. Using the HAMD scale, treatment was assessed at baseline, after two and
four weeks. Significant differences were recorded at two and four weeks of therapy with
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a 67% response rate for the treated group compared to a 28% response rate in the placebo
group at week four (p<0.05 ). Improvements in depressive mood, psychological anxiety,
and difficulty initiating sleep were also noted. Frequency of adverse drug reactions were
not reported nor was an intent-to-treat analysis, a method of including all randomized
subject's data into the final analysis, regardless of whether or not they completed the trial
according to protocol. It is used to accurately represent the statistical magnitude of
benefit.

Another placebo-controlled trial, 72 patients classified as having major depression were
randomized to either a control group or treatment with 300 mg of standardized extract
three times a day (Hansgen, 1994). The HAMD and CGI were used to evaluate
depressive symptoms and overall efficacy. Again, significant improvements were noted
after four weeks. The response rate for patients taking the extract was 81% and 26% for
those on placebo (p<0.001). Two patients in the placebo group and one in the active
group reported adverse drug reactions.

Hypericum extract LI 160 (Jarsin-300) was studied in 39 patients suffering from
depressive and psycho-vegetative irritations (Hubner et al., 1993). They were treated for
four weeks with either placebo or at the daily dose of 900 mg (300 mg three times a day).
Approximately 70% of patients in the treatment group were free of symptoms after four
weeks as measured by HAMD scores, which were significantly lower than placebo.
Additionally, no adverse drug reactions were reported for either group.
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Similarly promising results were reported on the same brand of extract, Jarsin (Halama,
1991). A four-week trial involving 50 patients with mild or neurotic depression were
treated with either the extract or placebo. At the end of the treatment period, 60% of the
active group reported a significant improvement of symptoms while there was no
detectable change in the control group. Only one patient treated with the extract
complained of adverse drug reactions.

Additionally, LI 160 or placebo was used to treat sixty-five mild to moderately depressed
patients in a double-blinded randomized trial lasting six weeks (Schmidt, 1993). Once
again results favored active treatment significantly. Sixty-seven percent of patients
responded to the extract. The response rate for the placebo group was 27%. Fatigue and
itching were reported side effects of the active treatment.

In a multi-center trial, 116 patients were randomized to treatment with liquid extract or
placebo for six weeks (Harrer, 1991). Patients suffered from neurotic or reactive
depression and were assessed according to the HAMD. Thirty-eight percent of patients
treated with the Hypericum extract showed a reduction in depressive symptoms while
15% of patients on placebo improved. Two cases of adverse drug reactions were
reported for the Hypericum group and nine for the placebo group.

Quandt’s study (1993) consisting of 88 patients suffering from mild to moderate
depression studied the efficacy of a liquid formulatin of the extract compared to placebo.
The group treated with Psychotonin (liquid Hypericum extract, 30 drops three times a
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day) improved significantly. There were no reported adverse drug reactions for either
group. Schlich and associates (1987) reported comparable results when they treated 49
depressive patients with the same extract.

Neuroplant, which is a dried extract of Hypericum, was used by Reh and Laux (1992) in
this double-blinded controlled trial. Treatment continued for twice as long as most other
published trials with assessments performed at eight weeks. HAMD scores were
significantly lower, 70% decrease in baseline, in the active group compared to 45%
decrease in the control group. Unfortunately, the study had very little power with a
sample size of only 25 patients in the treatment group.

Attempting to address the issue of small sample sizes, this next trial enrolled 162 patients
with mild to moderate depression (Schrader, 1998). Compared to previous trials, a
relatively low dose of Hypericum was used—250 mg twice daily. However, similar
results were obtained as previously documented. The responder rate for the treatment
group was significantly greater than placebo, 56% versus 15% respectively (p<0.001).

The first large clinical trial conducted in the United States evaluated the efficacy of St.
John's Wort 300 mg given three times a day, increased to a maximum of 1200 mg if
necessary, compared to placebo in two hundred patients (Shelton, 2001). This eightweek trial conducted at 11 acedemic medical centers enrolled patients with moderate to
severe depression and assessed rate of change in HAMD scores in addition to response
rates as measured by HAMD or CGI scores. Neither change in baseline HAMD score
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nor response rates differed between groups. Even after stratifying the sample based on
initial severity of depression (those with a mean HAMD score greater than 22 and those
less than 22), there was no significant difference in rate of change in HAMD scores for
either group.

This study was criticized for a number of reasons. The gold standard for testing
inefficacy is a three-arm study comparing the new agent, placebo, and a reference drug
with known efficacy (Hawley, 2001). Since there was no reference drug, it is hard to
determine whether St. John's wort was truly ineffective or if the patients represented a
more treatment-resistant group. Furthermore, the placebo response of 18.6% was notably
lower than in most trials (Cott, 2001).

Another point raised was that the sub-group analysis of less severely ill patients only
included those with scores of 20 and 21 on the HAMD. Many argue that these score do
not adequately represent mild to moderate depression, and therefore, the lack of a
difference does not confer lack of efficacy in this population (Fugh-Berman, 2001). The
authors did clearly state this in their discussion.

The efficacy and tolerability of an extract, WS 5572 standardized to 5% hyperforin, was
studied against placebo in 72 patients with mild to moderately severe (HAMD scores of
at least 16 or more) depression (Kalb, 2001). The study was performed over a period of
approximately six weeks (42 days) and focused primarily on efficacy and tolerability of
the extract. Favorable results for WS 5572 were reported on all indicators as assessed by
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scales such as CGI and HAMD. Improvements could be detected as soon as day seven of
therapy. At day 42, response rate for the extract was 62% versus 43% for placebo.
Adverse effects were mild for both groups including three cases (8%) of upper
respiratory symptoms for active treatment, which may have not been treatment related.

In reviewing more recent literature, another extract, WS 5570, standardized to 0.120.28% hypericin and 3-6% hyperforin, was studied in a randomized, double-blinded,
placebo-controlled trial involving 375 outpatients (Lecrubier, 2002). The six-week study,
which took place in several centers located throughout France, enrolled patients suffering
from mild to moderate major depression as classified by the Diagnostic and Statistical
Manual (DSM-IV) criteria. At the end of the six-week period, patients were assessed to
determine the change in HAMD score from baseline as well as the melancholia subscore,
total score on the MADRS, the 58-item version of the Symptom Check List (SCL-58),
and the CGI.

Intent-to-treat analysis demonstrated a significant difference in mean change of HAMD
from baseline for treatment group compared to placebo. Patients with a higher initial
HAMD score (22 or more) experienced a larger treatment effect (greater magnitude in
score changes) than those patients with lower initial scores, suggesting that St. John's
Wort may be more effective for more severe forms of depression. Those responding to
therapy (using the typical definition of at least a 50% decrease in baseline score) were
significantly greater for the extract (52.7%) compared to placebo (43.3%) (X=4.04, df=1,
p<0.05, two-sided). Additionally, 24.7% of patients experienced remission (score of six
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or less on the HAMD) with the extract compared to 15.9% of patients in the placebo
group, which also represented a significant difference (X=4.55, df=1, p=0.03, two-sided).
All other secondary measures were positive for the extract compared to placebo.

This trial was one of the larger, well-designed trials conducted to date. It was published
just four months after another pivotal trial that demonstrated a negative outcome for the
herb. This trial is mentioned in a subsequent section, focusing on comparative therapy,
as it included a reference drug (Hypericum Trial Depression Study Group, 2002).

Several meta-analyses have analyzed both placebo-controlled trials against the extract as
well as those comparing standard antidepressant therapies. The inclusion criteria for each
of these differ somewhat. For example, the first meta-analysis by Linde et al. included 13
trials that compared the extract to placebo. An overall response rate of 55% was reported
for the Hypericum group while 22.3% was reported for placebo (Linde, 1996). Whereas,
Kim et al. employed much more rigorous criteria for study inclusion and identified only
two placebo-controlled studies that qualified. The pooled response rate for this analysis
was 73.2% for Hypericum and 37.9% for placebo (Kim, 1999).

Although some studies possess stronger methodologies than others, overall the evidence
purported in these double-blinded placebo controlled trials favors St. John's Wort in the
treatment of mild to moderate depression. Anecdotal evidence available over the
centuries of use in Germany adds strength to this argument of effectiveness. However,
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one must also consider the effectiveness of St. John’s Wort relative to the prescription
antidepressants before advocating its widespread use.

COMPARATIVE EFFICACY-ST. JOHN’S WORT
A number of studies have been conducted comparing Hypericum compounds with
conventional antidepressants. Trials such as these lend themselves to making stronger
arguments regarding the use of St. John's Wort since the efficacy of the comparator drugs
have been well documented. A criticism of many of the trials is the use of a lower than
standard dose of comparison drugs. One author reasons that chosen doses were on the
lower end of the acceptable therapeutic range to facilitate blinding of patients (Vorbach,
1994). At higher doses, the classic side-effects of TCAs may be evident. In addition to
this, one can argue that the doses of TCAs reported (e.g. imipramine 75 mg) are what
most patients receive in the outpatient setting (Wheatley, 1997).

The multi-center trial mentioned above (Vorbach, 1994) compared imipramine 75 mg
daily to the brand extract, Jarsin (LI 160) 900 mg daily in a randomized, double-blinded
trial. Success after six weeks was evaluated on the HAMD, and CGI scales. Both groups
significantly improved according to all three scales, but no inter-group difference was
detected. Similar findings were reported in another study comparing imipramine with
Psychotonin (Werth, 1989).

The extract LI 160 was again used to test efficacy against amitriptyline in this doubleblind, randomized trial (Wheatley, 1997). Patients with mild to moderate depression
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classified according to DSM-IV criteria and HAMD scores were followed for six weeks
and treated with either 75 mg daily dose of amitriptyline or 900 mg extract daily. Results
based on an intent-to-treat analysis revealed no significant difference in regards to
response rate and CGI severity scores. There was a clear advantage in tolerability for the
extract with 32% of extract patients withdrawing due to side-effects compared with 52%
of amitriptyline patients.

Woelk (2000) used imipramine as the comparator drug in this trial testing 324 outpatients
with mild to moderate depression. The dose used more closely approximated that
recommended by most prescribers, titrated over seven days starting with 25 mg twice
daily and increasing to 75 mg twice daily. The Hypericum extract ZE 117, standardized
to 02% hypericin was tested for therapeutic equivalence to the standard therapy. No
differences were documented between the two groups with respect to mean change in
HAMD scores from baseline to the end of week six. Again, tolerability favored
Hypericum with only 30% reporting adverse effects compared to 63% for impramine.

St. John’s Wort has also been evaluated in patients with more severe depression. An
ICD-10 code (severe episode of a major depressive disorder, recurrent, without psychotic
symptoms) designated inclusion in one controlled six-week trial (Vorbach, 1997).
Patients were randomized to 1800 mg LI 160 extract or 150 mg imipramine per day and
assessed according to the HAMD and CGI. Similar responder rates (35.3% for LI 160
and 41.2% for imipramine) and global assessments (61.2% for LI 160 and 70% for
imipramine) were found according to HAMD and CGI respectively. However, total
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HAMD scores and CGI “therapeutic effect” were not equivalent for the two groups with
imipramine fairing better in both. Tolerability, once again, was greatly favored toward LI
160.

Meta-analyses of trials comparing St. John’s Wort to standard antidepressants such as
amitriptyline have also been published. As mentioned previously, two separate analyses
yielded similar results (Linde, 1996 and Kim, 1999). Ten trials were identified in the first
analysis and reported a response rate of 63.9% for Hypericum versus 58.5% for the other
antidepressants. The second published meta-analysis of four trials involving standard
antidepressant therapies compared to Hypericum demonstrated response rates of 66.4%
and 64% respectively. Both analyses showed improved tolerability with the extract over
the standard TCAs with fewer drop-outs (12.6% vs. 16.2%) and less adverse effects
reported.

The majority of clinical research performed on this herb has supported the notion that St.
John’s Wort may well have a place in clinical practice for treating mild to moderate
depressive episodes. In order to better assess the possibility of it becoming the standard
of care, additional studies have been conducted against the more commonly prescribed
SSRIs. Three studies have examined the benefits of St. John's Wort in comparison to
sertraline, and three have used fluoxetine as the comparator.

Brenner et al (2000) studied a small group of patients diagnosed with major depression
based on DSM-IV and a score of at least 17 on the HAMD. A dose titration of 600 mg of
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LI 160 or 50 mg of sertraline was utilized for the first week of therapy at which time
patients were increased to 900 mg or 75 mg respectively for the remaining six weeks.
Response rates were comparable with no statistical differences between sertraline (40%)
or Hypericum (47%). Change in HAMD scores also did not differ. A post-hoc analysis
indicated adequate power of the study to detect treatment effect differences. Both
treatments were well tolerated with only two reports of adverse effects in each group.

A comparison of these two agents was reported in another small trial conducted in
Canada (van Gurp, 2002). Eighty-seven outpatients with major depression evidenced by
a score no less than 16 on the HAMD were randomized to receive either St. John's Wort
or sertraline for 12 weeks. Dose escalation was also allowed in this trial with 50 to 100
mg of sertraline used or 900 mg to 1800 mg of the extract.

Assessments were made based on the BDI, change in HAMD, as well as self-reports of
side-effects and compliance at various stages throughout treatment. The primary
outcome measured was change in HAMD, BDI, and difference in side-effects reported at
12 weeks. Intent-to-treat analysis failed to reveal any statistical differences in
measurements of efficacy between the treatment groups. In addition, St. John's Wort was
found to be better tolerated than sertraline.

The largest of all trials, jointly funded by the National Institute of Mental Health and the
National Center for Complementary and Alternative Medicine, studied a total of 340
patients diagnosed with major depression as determined by DSM-IV criteria, a HAMD
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score of at least 20, and a maximum score of 60 on the Global Assessment of Fuctioning
(Hypericum Trial Depression Study Group, 2002). Patients were randomized to receive
either the extract LI 160, standardized to 0.12% to 0.28% hypericin, placebo, or sertraline
acutely for eight weeks, then an additional four months for those exhibiting a response.
The primary efficacy end point was the mean change in HAMD scores at week eight.
Full and partial response was also measured based on CGI scores of 1 or 2 and HAMD
score of 8 or less or CGI of 1or 2 and HAMD score of 9 to 12, respectively.

Notably, no differences in change in HAMD score or full response rate were detected
among the three groups at week eight. However, sertraline was superior to both placebo
and Hypericum on the CGI-I (improvement) score at week eight, though this was a
secondary outcome measure. Adverse events were lower with Hypericum than sertraline,
but neither had reports of serious events.

Although this trial failed to demonstrate any benefit of the extract over placebo, the fact
that a well-known and previously evidence therapy for depression (sertraline) also failed
to demonstrate efficacy over placebo must be taken into consideration. Additionally, this
trial tested the extract in patients with more severe depression, most of whom had been
diagnosed with depression for greater than one year (32% greater than 2 years). Hence,
these patients may in fact have been more treatment resistant than those tested in other
trials. Though this study was methodologically sound, more questions were raised than
answers elucidated.
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Seventy patients with ICD-10 codes indicating mild to moderate depression were
randomized to receive either 150 mg twice daily of Hypericum extract (Calmigen) or
fluoxetine 20 mg twice daily (Behnke, 2001). Rationale for these unconventional doses
was not discussed. Equivalence was evaluated by comparing efficacy measured in terms
of percentage reduction in HAMD scores. Therapeutic equivalence was inferred based
on the Food and Drug Administration's recommendation stating that the study drug must
be 80% to 125% as efficacious as the comparator drug.

The mean HAMD score decreased by 50% in the Calmigen group while the fluoxetine
group showed a 58% reduction in mean score, each representing a statistically significant
decrease (p<0.001). Between group analysis, however, failed to demonstrate a statistical
difference in group mean scores (p=0.23). The overall response rate defined as >50%
reduction in HAMD score was 55% for the Calmigen group and 66% for fluoxetine
(p=0.41). Hence, the extract was approximately 83% as efficacious as fluoxetine. The
authors state this study demonstrated equivalence between Calmigen and fluoxetine
based on the predetermined definition of equivalence. However, given the small sample
size, the study may not have been powered adequately to detect a true difference.

An analysis of the literature on St. John's Wort and Prozac was compared to determine if
response rates were similar among the various trials (Voltz and Laux, 2000). The authors
included trials testing efficacy of either compound in patients identified as having mild to
moderate depression based on ICD-10 codes or scores of < 24 on the HAMD. Absolute
reduction and percentage reduction in HAMD scores were combined and compared for
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the two compounds. No difference in absolute or overall percentage reduction was
found. However, sample sizes were not taken into consideration, and therefore, this was
not a meta-analysis but rather a gross comparison of all studies. Due to the weakness of
the methodology, clinically relevant inferences are difficult to make. The authors admit
to this fact and state that these preliminary data suggest possible equivalence but rigorous
trials are recommended.

The most compelling multi-centered trial to date compares the efficacy and tolerability of
St. John's Wort extract Ze117 to fluoxetine (Schrader, 2000). A total of 240 outpatients
with initial HAMD scores between 16 and 24 were randomized to either 20 mg fluoxetine
daily or 250 mg Ze117 twice daily. The primary outcome measured was the change in
mean HAMD score, measured at week zero and week six. Equivalence was defined
prospectively as < 3 points difference in mean score at endpoint for the two treatments.
Intent-to-treat analyses were conducted on all variables. The two treatments were
determined to be equivalent based on the change in mean HAMD score of 7.25 (95%
Confidence Interval (CI): 8.1 to 6.4) for the fluoxetine group and 8.11 (95% CI: 9.0 to
7.3) for the extract group. Secondary variables measured were responder rate,
compliance, mean CGI, and safety. There were no differences noted in compliance rates,
change in CGI for items 2 or 3, or in patients’ self-assessments. Significant differences
were measured in responder rates (40% for fluoxetine and 60% for Hypericum extract,
p=0.05) and mean change in item 1 (level of improvement, with 1 being "very much
improved" and 2 being "much improved") of the CGI (1.3 for fluoxetine and 1.6 for the
extract, p=0.03).
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PHARMACOECONOMIC STUDIES OF DEPRESSION
Decision analysis is one particular method used to conduct cost-effectiveness analyses.
Because of its unique ability to yield information under conditions of uncertainty, this
approach has been taken by many researchers to evaluate costly, controversial, or
questionable drug therapies. In the field of mental health substantial pharmacoeconomic
research, specifically decision analyses, exists demonstrating the apparent demand for
and use of economic modeling.

In one study, Revicki et al (1997) compare cost-effectiveness and cost-utility of three
antidepressant therapies, nefazodone, imipramine, and fluoxetine. The study estimated
lifetime medical costs of treatment of depression from a managed care perspective and
calculated quality-adjusted life years (QALYs) as the measure of utility.
The main goal of the study was to assess the efficiency of using newer antidepressants
(nefazodone and fluoxetine) as first-line treatment. Each treatment was assessed
individually. Subsequently, a step-wise approach of using imipramine as a first-line
treatment then fluoxetine only when initial therapy failed was assessed. This allowed for
an evaluation of the financial impact resulting from initial choice of initial antidepressant.

The model was based on the expert opinion of a panel of primary care physicians,
psychiatrists, and a clinical pharmacologist in addition to information obtained from the
medical literature. Pathways in the model were based on ideal primary care practices.
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Probabilities between depression and remission were based on literature and the panel
members.

A salient feature of the model was compliance states. One assumption was that patients
would be in full, partial, or a non-compliant state and were able to transition between
compliance states over the course of future depressive episodes. The panel assumed a
greater percentage of patients would be compliant with fluoxetine and nefazodone due to
dosing and tolerability compared to imipramine.

For imipramine, 30% were assumed to discontinue treatment within the first six weeks.
Of the remainder, 40% would be fully compliant, 30% partially and 30% minimally
compliant. Nefazodone and fluoxetine were assumed to have the same compliance rates
since reports in the literature suggest higher compliance rates with newer antidepressants
compared to TCAs, and also there is little difference between once a day dosing and
twice a day dosing regarding compliance (Blackwell, 1979). Resultant rates for the two
were: 20% discontinue treatment after six weeks, and of the remaining, 50% fully, 30%
partially, and 20% minimally compliant.

QALYs were calculated by using standard gamble technique to estimate the utility of
taking one of the three drugs while remaining in remission then multiplying the estimated
life-expectancy for each treatment regimen. One year on nefazodone was rated at 0.87,
imipramine was 0.80, and fluoxetine was 0.86 on a utility scale of 0.0 to 1.0.
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Once the total costs for each treatment was determined, it was then divided by the QALY
for that treatment to yield cost-effectiveness ratios. Imipramine had the lowest life-time
medical cost, but the lowest QALYs. QALYs were greatest for nefazodone. When ratios
were compared, it became evident that nefazodone was the most cost-effective (lowest
cost per QALY) treatment approach.

A sensitivity analysis, substituting a range of values for point estimates that are not
certain, was performed on compliance rates, recurrence rates, and the discount rate. All
analyses were one-way except for the last, which varied both compliance and recurrence
rates. No substantial differences were noticed even when the discount or recurrence rates
were changed. Compliance had the biggest impact, but the newer antidepressants were
still found cost-effective even with equal compliance rates among all treatments.

Another study demonstrating the use of decision analysis used a decision tree to evaluate
oral antidepressant therapy in the management of major depressive disorders (Einarson et
al., 1995). The introduction of a new antidepressant, venlafaxine, spurred the interest in
researchers to conduct this study. Two models of clinical practice were developed to
track in- and outpatient management of major depressive disorders for approximately one
year. The comparator agents were SSRIs (fluoxetine and paroxetine), SNRI
(venlafaxine), heterocyclic (trazodone and maprotiline), and tricyclic (amitriptyline and
imipramine) antidepressants. To determine overall cost-effectiveness, the outcomes
measured were total direct medical costs and symptom free days.
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An expert panel was utilized to determined the medical management of patients with
major depression. Medical care such as lab tests, physician visits, and hospitalization as
well as amount and duration of drug were estimated for each treatment alternative.
Averaging the reimbursement rates of three HMOs' derived costs for medical treatment.
Drug costs were estimated by the acquisition cost published in the 1993 edition of the
Red Book multiplied by the number of tablets per day for each treatment regimen.

Data on success rates of each treatment were obtained through a separate meta-analysis
performed by the authors. SSRIs had the highest estimated outpatient success rate
(fluoxetine, 64.6%) followed by heterocyclic antidepressants (HCAs) (trazodone, 58.9%).
Venlafaxine and amitriptyline had the highest rate of response for inpatients (62.4% and
50.9% respectively).

The outpatient model followed patients through the course of treatment for one year.
Initial response to therapy was assessed at four weeks. Those failing to respond were
treated with a different drug (all drugs were backed up by a TCA, TCAs were backed up
by SSRIs) and reassessed at four weeks. Those responding were reassessed at six months
with all failures following the same pathway for initial failure, and all successes were
determined to be in remission for the remainder of time. The inpatient model was the
same except for a 14-day hospitalization period built in for those failing to respond to
therapy.
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Symptom free days were estimated by assuming that days following successful treatment
were symptom free since the patient would not be a burden on the health care system. In
this sense, a symptom free day is the same as a successfully treated patient. Therefore,
the results of the ratio comparing costs to effectiveness measured by clinical success
should yield the same result as the ratio comparing costs to effectiveness measured by
symptom free days. To no surprise, the most cost-effective agent was the same
regardless of whether symptom free days or clinical success was the outcome. The
lowest cost-effectiveness ratio in the inpatient model was obtained by the treatment
regimen employing venlafaxine as the initial therapy. For outpatients, HCAs were the
most cost-effective treatment regimen followed by SSRIs.

Sensitivity analysis was performed on drug and medical costs and clinical success rates to
determine how robust the results of the base case analysis were. Because more than two
treatments were being evaluated, a rank order stability analysis was used to confirm the
base case results by yielding elasticity values. Elasticity values greater than one indicate
that the key variables (e.g. drug or medical costs) factored into the statistical basis of
relative cost-effectiveness ratios, when varied, will compromise the rank order and
undermine stability. All elasticities were less than one, confirming the initial results
obtained.

The prevalent use of economic modeling is global. The Canadian Journal of Psychiatry
published an article on the direct cost of treatment of depression with paroxetine
compared to imipramine (Lapierre, 1995). A computer-simulated decision tree was
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developed to model treatment patterns of depression over a twelve-month period.
Effectiveness data were obtained from the literature as well as a physician panel. Costs
associated with medical management and pharmacotherapy were obtained from the
Ontario Ministry of Health and the Ontario Drug Benefit Formula respectively.

The model developed follows patients through a typical clinical pathway in which initial
treatment prescribed is either continued or discontinued due to failure to respond.
Patients continuing treatment either complete a course of treatment for six weeks or
relapse. Those continuing treatment are reassessed at six months and either end therapy
or relapse. All relapses are followed by a second six-month course of treatment with the
same drug. Initial failure on treatment is followed by changing the drug, hospitalization,
electroconvulsive therapy, or visiting another physician and repeating the pathway stated
above. Probabilities associated with each clinical pathway were estimated by the
physician panel.

Data for the modeling of continuation, dropout, and relapse rates were obtained from
three separate double-blinded randomized controlled trials. The first trial compared
paroxetine to imipramine and reported continuation (response/tolerance) rates of 57.5%
for paroxetine and 46.4% for imipramine. The second study compared paroxetine to
placebo and reported a relapse rate of 5% at six months for paroxetine. A separate longterm study of six months duration comparing imipramine to placebo was used to obtain a
relapse rate of 20% for imipramine. To remain conservative, the model used 10% relapse
rate for each treatment.
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Once the base case variables were entered into the model and cost-effectiveness ratios
were calculated, sensitivity analyses were performed. The following variables were
evaluated over a given range: price of paroxetine, cost of hospitalization, relapse rate for
both drugs, and the continuation rate for paroxetine. One-way analysis was performed on
each.

It was determined that management of major depression with paroxetine produced a
lower annual direct cost than that of imipramine. Despite the ten-fold higher acquisition
cost of paroxetine, it yielded a lower cost of treatment failure, which accounted for a
majority of the total direct cost of treatment. Cost of hospitalization was the only
variable that affected the outcome of the analysis, as demonstrated in the sensitivity
analysis. As the cost of hospitalization decreased, imipramine became more costeffective. A two- or three-way sensitivity analysis may have resulted in more variables
impacting the final result.

The same treatment alternatives, paroxetine and imipramine, were evaluated in an earlier
study published by Jonsson and Bebbington (1994). They also used a decision analytic
model to evaluate cost-effectiveness of treatment for major depression. A third party
perspective was taken to assess costs over a period of twelve months.

A panel of experts, psychiatrists, general practitioners, and hospital pharmacists,
developed the possible clinical pathways in the model. Initial choice of treatment was
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either successful or the patient discontinued (measured by dropout rate) therapy. The
probability of drop out for each treatment was based on a pooled analysis of six
randomized double-blinded placebo-controlled trials that lasted six weeks. The rate of
dropouts for paroxetine was 42% and 56% for imipramine. In the model, all dropouts
switched drug therapy so one full course of each treatment (paroxetine and imipramine)
was included in the cost of treatment failure.

If a patient did not drop out, they were considered a treatment success. The possibility of
relapse was included for all successfully treated patients. Those relapsing were treated
with a second course of therapy and reassessed. Again, patients were either successful or
dropped out of therapy after relapse treatment. The relapse rate was established by panel
members as 25% for each treatment.

Expected costs for each pathway in the model were calculate by multiplying the cost
associated with the outcome of each pathway by the probability of that outcome
occurring. The cost-effectiveness of each treatment was calculated as cost per
successfully treated patient. Paroxetine had a lower expected cost than imipramine
therapy and ended up being more cost-effective than imipramine.

The results proved to be very stable when sensitivity analyses were conducted. All mean
values in the model were substituted with the extreme values included in the range given
to each variable. The variables that are mentioned in the article as being varied over the

57

lowest and highest possible values were cost of hospitalization, effectiveness of
treatment, and cost of treatment failure.

Hospitalization costs had no baring on the results since this represented such a small
fraction of overall cost of treatment. Cost of treatment failure however, did prove to be
rather sensitive though did not change the outcome. As the cost of treatment failure
decreased, the expected cost of paroxetine drastically decreased. However, the expected
cost of imipramine remained relatively unchanged. Both the highest and lowest values
of treatment failure resulted in paroxetine having the lower cost-effectiveness ratio. For
the variable success, as the rate of success increased for paroxetine and remained constant
for imipramine, paroxetine became more cost-effective until the point of dominance,
where the treatment offers better effectiveness at a lower cost. At the lowest end of
success (50% for paroxetine), imipramine had a lower expected cost but a higher costeffective ratio.

A recent review of pharmacoeconomic studies of SSRIs included the four studies
discussed above in addition to several others that used decision models to assess costeffectiveness (Frank, 2001). The Canadian Coordinating Office for Health technology
Assessment (CCOHTA) assessed cost per QALY of three treatment scenarios, initial
treatment with an SSRI followed by TCA, TCA followed by an SSRI, or TCA therapy
alone (Baladi, 1997). The model followed treatment over a period of 9 months and
outcomes were analyzed based on a third party payer perspective.
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The parameter for success was continuation on treatment without relapse or therapy
disruption. Data from a previous trial was used to determine QALYs, whereas
probabilities and costs were derived from meta-analysis from randomized clinical trials
plus expert opinion and claims data from Quebec, respectively. Direct medical costs
were highest with TCA alone ($1779). The SSRI to TCA strategy was $1334 compared
$1214 for the TCA to SSRI strategy. However, the treatment strategy utilizing an SSRI
as initial treatment with subsequent treatment failures switching to TCAs resulted in the
lowest cost per QALY and therefore the most cost-effective alternative.

CONCLUSION
What has been learned thus far is that since the introduction of TCAs, there has not been
any tremendous improvement regarding efficacy of antidepressants. However, the safety
and adverse effect profiles of drugs such as fluoxetine have made significant advances
toward improved compliance, tolerability and dosing. To date, a number of studies have
been conducted comparing the TCAs and heterocyclic compounds to newer therapies
such as the SSRIs and SNRIs. Since these compounds have made such vast
improvements in therapy regarding safety and side-effects but carry with them high price
tags, cost-effective analyses were warranted.

Their relatively expensive price may actually be commensurate with these enhanced
features if utilization of health care services is decreased with their use. Reviewing the
literature, it is apparent that decision analysis modeling is a popular method of evaluating
drug therapy. Many cost-effective analyses have sided in favor of the newer drugs such
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as paroxetine over the less costly TCAs or HCAs specifically for this reason-- a decrease
in physician visits and hospitalizations, which in turn drastically lowers total costs of
care.

By the same token, any new antidepressant therapy on the market possessing improved
qualities needs to be evaluated based on the best alternative currently being utilized.
Only then will the results of the study possess external validity (Luce and Simpson,
1995). St. John’s Wort has been evaluated in patients with mild to moderate depression
and in one study testing its use in severe depression. Comparisons of efficacy have been
directed toward standard TCAs such as imipramine and amitriptyline and against
placebo. Also, open label studies following patients in a clinic setting have evaluated
effectiveness.

All of these studies have taken a clinical perspective, assessing side-effects, safety, and
efficacy. Though use of modeling to evaluate cost-effectiveness of antidepressants has
been demonstrated to be widely used and accepted, there are no studies to date that
examine St. John's Wort vis-à-vis fluoxetine, the two therapies proposed in this project.
In fact, no evaluation of clinical parameters in combination with its economic impact has
been done.

To get a better picture of where this extract fits in the treatment algorithm for mild to
moderate depression, a cost-effective analysis is warranted. The previous data seem to
point to the conclusion that St. John's Wort may be just as effective as prescription
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antidepressant therapies in the treatment of mild to moderate depression. However, the
question still remains whether or not St. John's Wort is more cost-effective than
prescription alternatives.

In the absence of any published information regarding relative cost-effectiveness, it is
wise to compare St. John's Wort to one of the most commonly prescribed antidepressants
in the outpatient setting. Fluoxetine, given its frequent use and now generic availability,
shall serve as a representative of the class of SSRIs to which alternative treatments shall
be compared. This study shall serve as a model comparison of the extract against
fluoxetine comparing clinical and economic parameters using the method of decision
analysis.
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CHAPTER 3
METHODS

INTRODUCTION
The purpose of this study is to evaluate the relative cost-effectiveness of St. John's Wort
compared to fluoxetine based on a third party perspective for the treatment of mild to
moderate depression. The majority of third party payers restrict coverage of
pharmacotherapy to prescription status drugs only. St. John's Wort is currently an overthe-counter herbal supplement. It is noteworthy however to consider the effect of
increasing the scope of coverage to include St. John's Wort for the treatment of major
depressive disorders (MDD) including mild to moderate depression, if the therapy proves
to be a more cost-effective alternative.

To maximize external validity, St. John's Wort is compared to the current standard of
therapy as determined by a panel of experts with experience in treating this disorder.
Fluoxetine, the comparator drug, is used as a representative of the class of drugs known
as SSRIs (selective seratonin re-uptake inhibitors). This class of antidepressants are the
most often used for the treatment of MDD (Sclar, 1998).

The main goal of the study is to assess the cost-effectiveness of St. John's Wort relative to
that of fluoxetine when used to treat patients diagnosed with mild to moderate depression
managed entirely in an outpatient setting. Due to the exclusion of patients with more
severe debilitation, it was felt that these patients would not require hospitalization.
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Additionally, it was felt that this exclusion would better represent real-world costs given
the chronic nature of the disease commonly being managed in primary care clinics. In
order to attain this goal, the following objectives shall be met:

Objective A. Calculate the expected cost associated with the treatment of mild to
moderate depression using fluoxetine at the initial dose of 20 mg once a
day.

Objective B. Calculate the expected cost associated with the treatment of mild to
moderate depression using St. John's Wort at the initial dose of 300 mg
three times a day.

Objective C. Assess the overall cost per successfully treated patient (cost-effectiveness)
of St. John's Wort.

Objective D. Assess the overall cost per successfully treated patient (cost-effectiveness)
of fluoxetine.

Objective E. Assess the incremental cost-effectiveness of St. John's Wort compared to
fluoxetine.

Objective F. Assess the robustness of the findings by performing sensitivity analyses.
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Identification of the research question, the alternatives, and the objectives of the study
establishes the conceptual framework for cost-effectiveness analyses (Bootman, 1996).
In order to expand upon this framework and achieve the stated objectives, a decision
analysis model was created to capture the production relationship involved in the
treatment of depression in the clinical outpatient setting. The production relationship
identifies and quantifies outcomes (health and resource) for each alternative therapy and
provides the technical framework for the assessment of cost-effectiveness for both drugs.

Several advantages exist in utilizing the decision analytic approach to model the
treatment of depression. The flexibility of models allow for varying durations of
treatment, numerous treatment options to be compared, and the clinical scenario can be
based on real-life practice as opposed to controlled settings of randomized controlled
trials. Models typically extrapolate data beyond that which has been studied. Also, they
can provide information relative to decision-makers in a timely fashion.

DECISION ANALYSIS
Decision analysis is a method of breaking down a problem or question into stepwise
outcomes and assigning a utility or cost to each outcome. The delineation of outcomes
can be represented in a structure called a decision tree, the tool used in this study to
calculate the cost-effectiveness ratios. The tree enables visualization of different choices
and chances represented in a clinical scenario (Lawler, 1995).

64

Within the structure of the decision tree, there are two forms of nodes, a probability or
chance node and a decision node. The decision node represents a place in the tree where
a decision or choice must be made (the initial question at hand). In this model, the
decision node is followed by the treatment choices St. John’s Wort and fluoxetine. A
chance node occurs after a decision has been made and two or more outcomes follow.
Each of these outcomes has a probability of occurring, which is represented by the value
or definition given to the chance node and must equal 1.0 when the branches of that node
are summed. The branches of the tree expand until all relevant outcomes have been
identified and a final outcome is reached, which is called the terminal or payoff node
(Lawler, 1995).

The number of outcomes or branches of the tree can be very extensive and depends to
some extent on the scope of the analysis. Based on the scenario being modeled, a time
frame must be defined. Determining the length of time for which a decision is modeled
helps to establish the extent of the decision tree.

Once the structure of the tree is drawn with all relevant outcomes included, the next step
is to assign probability estimates and costs and/or utilities associated with each outcome.
Ultimately, probability estimates are based on clinical studies with good methodological
quality that represent well the population being studied. Unfortunately, data are not
always available even in the vast medical literature that is published. In those instances,
it is necessary to rely on expert opinion. It is important to remember that the stronger the
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evidence used in the model, the more robust the inference one can make from the results
of the model (Richardson and Detsky, 1995).

The next estimates to be entered into the tree are the costs associated with each outcome.
Criteria used to establish costs depend on the chosen perspective of the study. Following
the incorporation of all relevant data, the model is then analyzed. The process employed
in the calculation of cost-effectiveness is called “folding back” the tree. In this process,
probability estimates for each outcome are multiplied by the cost of the outcome and
these products are then added together. It begins at the terminal node and folds back
toward the root (decision) node until an expected value is calculated for each decision.
The best decision based on the assumptions and criteria defined (lowest cost per highest
benefit) can then be determined.

As stated previously, some of the data programmed in the tree are not certain but are best
guess estimates or underlying assumptions. It is of particular interest to test these
estimates over a range of values to see how the final decision is affected. This process is
called sensitivity analysis (Tom and Schulman, 1997).

Each uncertain variable is defined by a plausible range of values on which the analysis
will be based. Varying one variable at a time is called one-way sensitivity analysis.
Changing the value of a number of different variables at the same time leads to multi-way
sensitivity analysis. In executing this type of analysis, the robustness of the data is tested;
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it can be determined to what extent each variable or assumption is a predictor of the final
outcome.

The decision tree model for this study was developed using the software Decision
Analysis by TreeAge (DATA 3.0). This software program allows for the use of variables
to define or represent probability and payoff values. Using this method allows for the
calculation of base case (best guess) results and later changing those estimates that are
uncertain or thought to be important predictors of the final result to yield best and worse
case scenarios. DATA is similar to other decision analytic software such as SMLTREE
(James Hollenberg, 526/625-4332) and Supertree (Strategic Decisions Group, Menlo
Park, CA.).

DATA calculates cost-effectiveness ratios by first deriving the expected cost at each
chance node then the expected effectiveness and subsequently divides expected cost by
expected effectiveness. The minimum of the two ratios is then found and illustrated in
the tree. Another feature available is ranking analysis. This procedure allows for the
calculation of marginal cost, marginal effectiveness, and marginal cost-effectiveness at
each decision node.

Once all base case analyses have been employed to derive the final outcome, sensitivity
analysis can be used to test the robustness of the data. DATA allows for the calculation
of one-way, two-way, and multi-way sensitivity analysis. Each result can be presented in
graphic form with the indifference value indicated. The point of indifference, also called
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threshold value, indicates the value that renders no difference in cost-effectiveness
between treatments. Given the availability of the software and its sufficient technical
capabilities, it represented a viable choice for the completion of this study.

The primary objective at the outset of this project was to evaluate the potential of a new
antidepressant herbal, St. John's Wort, in terms of its cost-effectiveness when used to
treat mild to moderately depressed patients on an outpatient basis. According to the
literature, the current standard of therapy for the treatment of these patients is fluoxetine.
Its proven efficacy and popularity among practitioners is evidenced by its status as the
number one prescribed antidepressant.

In order to maximize external validity, it is necessary to compare the therapy being
questioned with its best alternative currently available (Luce and Simpson, 1995).
Hence, fluoxetine was chosen as the alternative to which St. John's Wort was compared
based on relative cost-effective ratios. This comparison was made under the assumption
of specific treatment indications.

Treatment indication refers to the specific drug treatment regimen applied to a specific
patient population (Eddy, 1992). Starting with initial treatment regimens, St. John's Wort
is evaluated based on 300 milligrams (mg) extract given three times daily while
fluoxetine is evaluated on the initial dose of 20 mg given once daily. The indication
modeled in this study is the treatment of an adult patient, age 18 to 65, with a first time
diagnosis of mild to moderate depression with no suicidal ideation. The treatment is
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entirely on an outpatient basis only and is modeled for a period of one year, following the
recommendations of the expert panel and the American Psychiatric Association (APA)
that patients remain on therapy for a period of six to twelve months to decrease chance of
relapse (APA, 1993). The perspective of the study is based on a third party payer
viewpoint. Consequently, only direct costs of medical treatment encountered by patients
are accounted for in the model and are described in detail in the cost analysis.

MODEL DEVELOPMENT
It was highly desirable to model the treatment of depression based on actual clinical
practice patterns. Therefore, a panel of experts was identified to help establish the
clinical management pathway for the outpatient treatment of depression that ultimately
provided the structure of the decision tree (Figure 3.1).

Figure 3.1: Decision Tree for Treatment of Mild to Moderate Depression

D/C = discontinue; NC = non-compliant; Rx = treatment; SE = side-effects; SJW = St. John’s Wort

69

The panel consisted of two psychiatrists, one pharmacist who specializes in psychiatry,
and three primary care physicians all experienced in the diagnosis and management of
major depressive disorders.

Panel members were asked several questions related to clinical practice and were
instructed to base their answers on the following clinical scenario. A patient (nongeriatric, non-pediatric) presents to the outpatient setting with symptoms consistent with
a diagnosis of major depressive disorder (MDD). This is the first episode experienced,
and it is assessed to be of mild to moderate severity of illness with no suicidal ideation.
Also, no comorbidities that would interfere with antidepressant drug therapy are present.

A modified delphi technique was used to gather information about the clinical
management of patients (Fink, 1984). Results of the interviews were aggregated in
tabular form. If total agreement was not reached, the majority response was used. The
questionnaire and consensus responses are presented in Appendix A.

The choice of the alternative, fluoxetine, was agreed upon by the panel members as an
appropriate comparator for the study. All agreed that SSRIs were the most commonly
prescribed therapy and fluoxetine was a good representative for the class. Several of the
panel members explained their rationale for choosing one drug over another in this class
was usually based on the small differences in the side-effect profiles. The initial dose
chosen was 20 mg daily. This is supported by the package insert and the most common
dose used in clinical trials. However, the panel estimated that approximately 25% of
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patients require a higher dose of 40 mg daily. This was taken into consideration when
determining cost of drug therapy and is presented in the cost analysis section.

The panel was then asked several questions regarding the management of patients
diagnosed with depression. It was established that all patients would have a baseline
thyroid stimulating hormone or TSH level drawn during the initial visit. The panel
referred to the Diagnostic and Statistical Manual (DSM) as the primary criteria on which
the diagnosis is made. The psychiatrists were more likely to rely on depression scales
like the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Rating Scale
(HAMD) to assess response, but in general all members agreed that the clinical interview
evaluating the patient’s self-assessment of improvement in DSM criteria was most often
used. Definition of success as depicted in the model, however, is based on that defined in
clinical trials as at least a 50% reduction in baseline HAMD score.

Assessment of response and side-effects was determine to occur between two and four
weeks. All members agreed that if an adequate response was not achieved, the patient
would be switched to another SSRI. The model assumes treatment failures are switched
to paroxetine (Paxil). The panel agreed that this is a reasonable assumption given that
clinical experience has shown that failure to respond to one SSRI does not preclude
response to a different SSRI. Additionally, the APA guidelines support changing to a
medication from the same class after initial failure to respond (APA, 1999).
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For both drugs, the panel estimated that the average number of physician visits a patient
would have was six per year. The panel estimated that if a treatment failure or relapse
occurred, the number of physician visits would increase to seven per year. For
successfully treated patients, visits would occur at weeks two and four then at months
four, six, nine, and twelve. For patients experiencing treatment failures, visits would
occur at weeks two, four, and eight then at months four, six, nine, and twelve. All
patients were assumed to have five psychotherapy visits, which involved individual
counseling by an experienced psychologist. For treatment failures or relapses,
psychotherapy visits increased to six per year. Success was defined as a 50% decrease in
baseline score for the HAMD, which is called response rate in clinical trials. Failure,
therefore is simply the complement of success (1- response rate).

Two possible outcomes could occur for patients achieving a successful response to
therapy. Due to intolerable side-effects, patients would discontinue the drug for which
drug treatment would then be changed to paroxetine. Paroxetine is consistently used to
represent the second choice of drug therapy due to initial treatment failure, relapse, and
discontinuations for both drugs. The panel agreed that an additional visit would be
required for patients that failed to respond to initial therapy.

If the side-effects were tolerable, patients would continue treatment for six months.
Many patients require additional therapy to combat side-effects. The most common sideeffect of fluoxetine that requires medical treatment, according to the panel, is anxiety that
causes insomnia, which usually occurs within the first two weeks of therapy. Trazodone

72

50 mg at bedtime is frequently prescribed for this side-effect. An assumption for those
continuing treatment is that a percentage will require trazodone (fluoxetine arm only).
Panel members cited trazodone as the most commonly prescribed treatment for sideeffects due to fluoxetine. Headache and gastro-intestinal upset were other common sideeffects reported. However, treatment for these adverse effects was assumed to be overthe-counter medications and therefore, was not included in the model.

At six months, a reassessment occurs and possible outcomes are remission, relapse due to
noncompliance, and relapse due to ineffectiveness of treatment. The panel agreed that
patients in remission would continue drug therapy at the same dose for an additional six
months for a total of one year of drug therapy. One year was described by the expert
panel as a standard length of therapy. The APA along with Agency for Health Care
Policy and Research (AHCPR) guidelines suggest treatment of major depressive
disorders be continued for a period of at least 16 to 20 weeks after the initial response has
been achieved to minimize the chance of relapse. Hence, the model was based on one
year of treatment in order to capture all relevant costs associated with treatment of this
disorder, including relapse.

EFFECTIVENESS DATA
A search for published trials on St. John's Wort and fluoxetine was performed using
MEDLINE, PSYCHLIT, EMBASE, and the Cochrane Database with the terms St. John’s
Wort, Hypericum, hypericin, fluoxetine, Prozac, depression, and depressive disorder
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along with the appropriate Boolean operators. Inclusion criteria used for the selection of
effectiveness data were studies published in English that randomized patients between
groups, in an outpatient setting, utilized a control group comparing either placebo or
standard antidepressant therapy, assessed patients at least 18 years of age diagnosed with
depression, defined response to treatment as 50% or more reduction in HAMD baseline
score, and evaluated response over a period of at least four weeks.

Additionally, the minimum dose of fluoxetine accepted was 20 mg daily. While no dose
requirement was established for St. John's Wort, studies were limited to those testing
single-entity products only. Exclusion criteria were studies testing severe depression,
those involving an inpatient component, St. John's Wort products containing other active
ingredients (combination products), and patients with co-morbid psychiatric conditions.

EFFECTIVENESS OF ST. JOHN’ WORT
The results of the search on St. John's Wort yielded 174 relevant records, of which 36
were clinical trials. A review of these records revealed that the majority of studies tested
subjects with mild to moderately severe depression assessed by the HAMD scale. Most
were clinical trials carried out on a small sample of patients classified with some type of
depressive disorder according to ICD-9 (diagnostic) codes or DSM-III R criteria. A total
of 32 trials met the inclusion criteria. Three studies comparing St. John's Wort to
fluoxetine were identified.
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In the first study a total of 240 outpatients with initial HAMD scores between 16 and 24
were randomized to either 20mg fluoxetine daily or 250mg Ze117 twice daily (Schrader,
2000). The primary outcome measured was the change in mean HAMD score, measured
at week zero and week six. Equivalence was defined prospectively as less than or equal
to three points difference in mean score at endpoint for the two treatments. Intent-to-treat
analyses were conducted on all variables.

The two treatments were determined to be equivalent based on the change in mean
HAMD score of 7.25 (95% Confidence Interval (CI): 8.1 to 6.4) for the fluoxetine group
and 8.11 (95% CI: 9.0 to 7.3) for the extract group. Secondary variables measured were
responder rate, compliance, mean clinical global impression (CGI), and safety. There
were no differences noted in compliance rates, change in CGI for items 2 or 3, or in
patients’ self-assessments. Significant differences were measured in responder rates
(40% for fluoxetine and 60% for hypericum extract, p=0.05) and mean change in item
one of the CGI (1.3 for fluoxetine and 1.6 for the extract, p=0.03). The most common
adverse effect in the fluoxetine group was agitation occurring in 7.9% of patients, while
gastrointestinal disturbances were most common in the extract group occurring in 4.8%
of patients. Only one patient withdrew due to side-effects in the fluoxetine group.

The second and third studies were determined to be of little value due to the small sample
size (Harrer, 1999 and Behnke, 2002). The lack of power precludes the ability to detect
relatively small but clinically significant differences. Additionally, the more recent trial
used a fluoxetine dose of 20 mg twice daily, which is an unconventional regimen and the
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authors failed to report response rates. Therefore, the study failed to meet all the
inclusion criteria.

Given that only one study comparing St. John's Wort to fluoxetine was identified and not
all variables needed for the model were measured, it was decided to explore studies
comparing different alternatives than those studied in this model (mainly St. John's Wort
versus tricyclic antidepressants (TCA). It was particularly desirable to identify a metaanalysis that met the criteria previously established. In general, meta-analyses are
preferred to a single clinical trial for use in decision analysis. A more heterogenous
population and different clinical settings are represented, which aids in the
generalizability of the results. Additionally, studies comparing St. John's Wort to
standard antidepressants were given higher priority over placebo controlled trials due to
the fact that St. John's Wort is modeled in this study as a potential substitute for current
therapy and not as an adjunctive therapy. Three meta-anlyses were identified that met the
inclusion criteria.

A meta-analysis by Whiskey et al. (2001) identified nine studies comparing St. John's
Wort to standard antidepressants. Of those, four met the stricter methodological criteria
of intent-to-treat analysis, sufficient power to detect statistical differences, and use of an
effective dose of comparative antidepressant. The response rate ranged from 43% to 76%
for St. John's Wort. The pooled number of drop-outs due to adverse drug reactions from
all trials was 2% for St. John's Wort (n=689) and 10% for fluoxetine (n=79).
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Kim et al. (1999) performed a similar meta-analysis on four trials comparing St. John's
Wort to TCAs. A pooled response rate of 64% was derived for St. John's Wort and
66.4% for TCAs. One trial that did not include an intent-to-treat analysis was included
which was excluded from the previous meta-analysis. Drop-out (discontinuation) rates
were also reported as 12.6% for St. John's Wort due to side-effects or insufficient
efficacy. Headache, gastrointestinal upset, and dizziness were the most commonly
reported side-effects.

A meta-analysis by Linde et al. (1996) provided a comprehensive overview of
randomized clinical trials that assessed the antidepressant effects of St. John's Wort
against either placebo or standard TCAs. The results of the meta-anlysis provided four
separate response rates. Studies were stratified based on control group (placebo or
standard TCA) and hypericum (single source or combination) product. Within each of
these categories, responder rates, dropout rates, and side-effects are reported.

The responder rate calculated from the three studies that compared single preparations of
St. John's Wort to standard antidepressant therapies (amitriptyline, imipramine, and
maprotiline) was 64% for St. John's Wort and 59% for TCAs. The analysis by Kim in
1999 differed from this by only one study, which was published after Linde’s analysis
was conducted, yet yielded the same result in response rate. The drop-out rate for
Hypericum groups was 4% and the percentage of patients reporting side-effects was 20%.
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Since two of the meta-analyses yielded the same response rate and the third failed to
report a pooled statistic, the response rate of 64% was chosen to represent the probability
of successful treatment with St. John's Wort. This figure is relatively consistent with that
reported by Schrader et al comparing St. John's Wort to fluoxetine. In that study, the
response rate was 60%. Therefore, it seems reasonable to use 64% given it is based on a
larger data set. The response rate range (43% to 76%) reported by Whiskey et al. was
chosen to represent the range over which the sensitivity analysis for this variable was
conducted.

Given the limited amount of data on St. John's Wort and the relative lack of clinical
experience with the drug, conservative estimates (in terms of favorable outcomes) were
chosen for most variables. The drop-out rate was chosen as 12.6% since this was the
highest estimate reported. As reported in clinical trials, the most common side-effect is
gastrointestinal upset relating to nausea, vomiting, abdominal discomfort and
constipation. None of which would require prescription treatment. Therefore, the
occurrence of side-effects for St. John's Wort was not included in the model as it is
assumed not to have any associated direct medical costs from the payer’s perspective. If
however, these side-effects caused discontinuation of treatment, then the treatment
strategy would be to change therapy. This is represented in the decision tree by
probability of discontinuation of treatment.

There is a lack of long term data published on St. John's Wort. The literature search was
unsuccessful in finding estimates on remission and/or relapse rates. Therefore, these data
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were based on the estimates obtained for fluoxetine. In each case, a more conservative
estimate for St. John's Wort was assumed. Additionally, only limited information was
found on compliance.

In general, patients are less compliant with thrice-daily regimens than once-daily
regimens. This was evidence in a trial testing the affect number of doses has on
compliance (Eisen, 1990). This study used a computerized device to record the number
of times the medication container was opened. Three-time daily regimens were
associated with more than two times the non-compliance rate than daily regimens.
Hence, the value for relapse due to noncompliance for fluoxetine was doubled for St.
John's Wort. A summary of the probability estimates is presented in Table 3.1.

Table 3.1: Base-case and range probability estimates for St. John’s Wort
PROBABILITY ESTIMATE
SUCCESS
DISCONTINUATION OF RX
REMISSION
RELAPSE DUE TO
NON-COMPLIANCE

ST. JOHN’S WORT
(RANGE %)
64% (43-76)
13% (2-52)
40% (20-65)

DATA SOURCE
META-ANALYSIS1, 2
META-ANALYSIS1
N/A

40% (10-85)

EISEN et al. 1990

1 Kim et al. 1999; 2 Linde et al. 1996; N/A=none available; RX=treatment

EFFECTIVENESS OF FLUOXETINE
As a result of the literature search, it was apparent that effectiveness data on fluoxetine
was more readily available than that on St. John's Wort. Fluoxetine has been on the
market for more than a decade and is heavily relied on for its antidepressant effects.
However, products containing St. John's Wort are fairly new to this country; its use as an

79

antidepressant, until recently, have been virtually unknown. Consequently, it was highly
desirable to find effectiveness data from studies that were similar in methodology to that
of effectiveness data on St. John's Wort.

The abundance of randomized clinical trials testing the efficacy of fluoxetine for the
treatment of depression involved both inpatients and outpatients with moderate to severe
depression or other mental illnesses. Several meta-analyses were identified through the
initial search. In developing clinical practice guidelines for the treatment of depression,
the AHCPR conducted several meta-anlyses on newer antidepressant therapies including
fluoxetine (AHCPR, 1993).

The response rate was reported for studies conducted on outpatients in primary care with
MDD. Fluoxetine was reported to have a 47% response rate compared to other
antidepressants. The range for all SSRIs tested was 43% to 59%. Another meta-analysis
conducted by Einarson et al. (1995) stratified studies based on clinical setting of inpatient
or outpatient management of depression. They reported an overall success rate of 65%
based on 12 fluoxetine trials.

A more recent review of antidepressant therapy was published as an evidence report
summary (Williams, 2000). This review found no significant difference in efficacy
between fluoxetine and other SSRIs. An average response rate of 54% for newer
antidepressants was reported, however, nothing specifically for fluoxetine. Drop-outs
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due to adverse effects were 11% for SSRIs. Relapse rates were also studied. Ten percent
of patients on newer treatments relapsed within 24 weeks yielding a 90% remission rate.

In an effort to match the data obtained on St. John's Wort, it was highly desirable to
identify trials testing fluoxetine in patients with mild to moderate depression. The search
was successful in finding a meta-analysis that assessed response to fluoxetine based on
severity of illness (Pande, 1993). This study re-analyzed data from 19 double-blinded
randomized clinical trials of fluoxetine against placebo or TCA (amitriptyline,
imipramine, doxepin, desipramine or nortriptyline).

Patients were stratified into three severity levels (mild, moderate, and severe depression)
based on total HAMD scores at baseline. The results were then re-analyzed to yield
response rates for each stratum. In all groups, fluoxetine was more effective than placebo
with higher remission rates and as effective as TCAs with similar remission rates. The
response rate for fluoxetine compared to TCAs was 77% for the mild depression group
and 56% for the moderate depression group. The average of the two groups yields a
response rate of 67%. This study successfully illustrated the effectiveness of fluoxetine
for all severity levels of MDD. No significant differences in efficacy were found
between groups based on severity of illness. Given this important finding, use of the data
obtained from the studies described above was deemed acceptable.

Overall, published clinical success rates for fluoxetine range from 40% to 77%, which is
used as the range over which the sensitivity analysis was performed. Given this disparity,
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the actual base case estimate used in the model was derived from the expert panel who
reported an average of 63% of patients respond to therapy. This value is similar to that
reported by an expert panel used in a similar cost-effectiveness study (Einarson, 1995).

A pragmatic trial was identified in the search that evaluated effectiveness and costs of
fluoxetine in the outpatient setting compared to TCAs (Simon, 1996). The lack of a
controlled setting provides results that are much more generalizable and therefore,
relevant for inclusion in the decision analysis model. The rate of discontinuation due to
adverse-effects was 9% for fluoxetine. Clinical remission was achieved by 49% of
patients at six months for the fluoxetine group.

The best estimate found for remission rates was that published in the trial by Simon et al.
(1996); 49% was used as the base estimate with a range of 35% to 90%. The probability
of a discontinuation due to adverse-effects was estimated to be 9% in the model, based on
the same study. The expert panel however, estimated this to be approximately 20%.
Therefore, the estimate ranged from 2% (the average for placebo groups) to 20%.

The probability of relapse is the compliment of the probability of remission. Therefore,
the model estimated a 51% relapse rate for fluoxetine, ranging from 10% to 65%.
Compliance was built into the decision model as a component of relapse. No reliable
estimate of compliance was identified in the records obtained. In the trial studying
fluoxetine use in primary care, 61% of patients were compliant at three months (90 days)
as measured by number of refills obtained (Simon, 1996). However, this measure of
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compliance is not always the most accurate as patients may hoard medications, use
multiple pharmacies, and/or have access to sample medications.

Another study compared the effect of dosing regimens of anti-hypertensive medications
on compliance rates (Eisen, 1990). This trial used computerized technology to count the
number of times the medication bottle was opened and assumed each opening correlated
to ingestion of the medication. Once-daily regimens were associated with an 84% rate of
compliance while thrice-daily regimens fell to 59%. It is reasonable to assume these
rates will vary slightly depending on the medication being studied. Fluoxetine, though
much better tolerated in clinical trials than tricyclics, still has a number of bothersome
side-effects such as agitation, headache, nausea, sexual dysfunction, and weight gain.
Hence, the relapse rate due to non-compliance was assumed to be 20% as compared to
16% found for once-daily regimens. This figure was ranged from 5% to 40%.

The last variable, probability of agitation, was based on the rate published in the
Physicians Desk Reference of 20%. The expert panel estimated a similar rate of
occurrence. However, since the model assumed that every occurrence would require
treatment, the more conservative estimate of 10% was used for the base case analysis.
This base estimate was varied from 2% to 20%. A summary of effectiveness variables
for fluoxetine is presented in Table 3.2.
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Table 3.2: Base-case and range probability estimates for fluoxetine
PROBABILITY ESTIMATE
SUCCESS
DISCONTINUATION OF RX
SIDE-EFFECT RX
REMISSION
RELAPSE DUE TO
NON-COMPLIANCE

FLUOXETINE
(RANGE %)
63% (40-77)
9% (2-20)
10% (2-20)
49% (35-90)

DATA SOURCE
EXPERT PANEL
SIMON et al., 1996
PDR; EXPERT PANEL
SIMON et al., 1996

20% (5-40)

EISEN et al., 1990

PDR=Physicians Desk Reference, 2002; RX=treatment

COST DATA
Cost information for direct medical care was based on charges obtained from a primary
care clinic in Guilford, Connecticut as well as an outpatient psychiatry clinic in New
Haven, Connecticut. Direct medical care included an initial evaluation and follow-up
visits to a primary care physician, an initial evaluation and follow-up visits to a clinical
psycologist for individual psychotherapy sessions, and a baseline thyroid stimulating
hormone (TSH) level.

Drug acquisition cost was based on 2002 Red Book Average Wholesale Prices (AWP)
for generic trazodone 50 mg, and brand Paxil 20 mg and 30 mg. The cost of generic
fluoxetine 20 mg and 40 mg was based on data from retail pharmacies nationwide
provided by Verispan, SPA for the time period of September 2001 to August, 2002 in
addition to the published AWP for generic fluoxetine. The panel estimated that
approximately 25% of patients require a dosage increase.
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To account for this, the cost of therapy for one week of Paxil was based on 75% of the
AWP for one week of 20 mg and 25% of the AWP for one week of 30 mg.

Example calculation: The average AWP for a 20 mg tablet of Paxil = $2.76
The average AWP for a 30 mg tablet of Paxil = $2.79
($2.76 * 75%) + ($2.79 * 25%) = $2.77 or $19.37 per week of therapy

The lower end of the cost range for fluoxetine was determined by using the average AWP
for generic fluoxetine and estimating that only 25% of this price would be paid by the
insurer. Third-party payers rarely reimburse 100% of the AWP as this price is inflated
compared to the acquisition cost to the pharmacy.

Example calculation: The median generic AWP for a 20 mg tablet of fluoxetine = $2.67
$2.67 * 25% = $0.67day or $4.67 per week of therapy

The highest end of the cost range for fluoxetine was determined by using the average
AWP for brand fluoxetine and estimating that 25% of patients require 40 mg daily while
75% require 20 mg daily.

Example calculation: The median AWP for a 20 mg tablet of Prozac = $3.55
The median AWP for a 40 mg tablet of Prozac = $7.10
($3.55 * 75%) + ($7.10 * 25%) = $4.44/day or $31.08 per week of therapy
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Cost of a 30-day supply of St. John's Wort 300 mg capsules taken three times per day
was based on the average price of six different brands sold at various retailers in Hamden
and Cheshire, Connecticut. Total cost of drug therapy for the year was estimated by
multiplying the average weekly cost by the number of weeks of therapy. Tables 3.3, 3.4,
and 3.5 provide a summary of the drug cost data.
Table 3.3: Direct medical costs associated with treatment of depression
VARIABLE
COST $ (RANGE)
DATA SOURCE
TSH LEVEL
25.00
PCC
MD VISIT (INITIAL)
145.00
PCC
MD VISIT (FOLLOW-UP)
85.00
PCC
PSYCOTHERAPY (INITIAL)
115.00
OPC
PSYCOTHERAPY (FOLLOW-UP)
75.00
OPC
ARP; Red Book,
FLUOXETINE
15.58^ (4.67-31.08)* 2002 AWP
ST. JOHN’S WORT
3.68^ (1.35-20.00)
ARP
Red Book, 2002
PAXIL
19.37^*
AWP
Red Book, 2002
TRAZODONE 50 mg
3.50^
AWP
ARP=average retail price of six different brands; AWP=average wholesale price; mg=miligrams;
OPC=Outpatient Psychiatry Clinic; PCC=Primary Care Clinic
^one week of therapy, *based on AWP calculation shown in previous section

Table 3.4: Average retail price of 30-day supply of St. John's Wort 900 mg
ST. JOHN’S WORT ($)
SOURCE*
5.79
PHARMAPURE
6.99
VITAMIN WORLD
11.97
GNC
13.99
GNC, ZE 117
16.18
HOMEBEST
20.58
KIRA, LI 160
*Retailers located in Cheshire, Connecticut, November 2002
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Table 3.5: Average retail price of 30-day supply of fluoxetine 20 mg
FLUOXETINE COST ($)
SOURCE*
49.68
WAL-MART
53.40
VERISPAN^
54.99
WALGREENS
74.99
RITE-AID
78.99
CVS PHARMACY
82.49
BROOKS PHARMACY
*Retailers located in Cheshire, Connecticut, November 2002; ^Verispan provides cost
information from retail pharmacies nationwide, compiled from September, 2001 to
August, 2002

The expert panel estimated utilization of medical care for each pathway represented in
the decision model. For Path 1, a patient successfully responds to initial therapy with
fluoxetine, then discontinues therapy due to adverse drug reactions. An initial physician
evaluation is performed then a follow-up visit is required to change therapy. The patient
is assumed to have five additional follow-up visits. Additionally, the patient has five
psychotherapy sessions, one initial evaluation and four subsequent visits. Drug costs for
this path involves four weeks of fluoxetine and 48 weeks of paroxetine (Paxil).

Path 2 involves the same scenario for patients initially responding to fluoxetine, then
continuing therapy but requiring treatment for side-effects, then subsequently going into
remission for the remainder of the year. The number of physician visits as well as
psychotherapy visits remains the same as Path 1. The expert panel estimated an average
of six physician visits per year would be encountered by patients. The occurrence of
side-effects requiring treatment or the need to change therapy would require an additional
visit.

87

The drug costs are represented by 52 weeks of fluoxetine, assuming full compliance, and
50 weeks of trazodone. The expert panel estimated that the majority of side-effects occur
within the first two weeks of therapy. Another assumption of the model is that patients
are fully compliant with the medication used to treat the side-effect.

Path 3 is similar to Path 2 except that the patient experiences a relapse by month six due
to medication non-compliance. Generally, non-compliance is defined as taking less than
70% of the prescribed medication. Therefore, Path 3 assumes the patient is only 69%
compliant with fluoxetine and trazodone both. Because relapse is based on noncompliance in this path, the model assumes that fluoxetine will again be prescribed and
taken for an additional six months at full compliance. This yields a total of 44 weeks of
fluoxetine and 34.5 weeks of trazodone costs.

Based on the expert panel, the patient would have an additional visit to re-evaluate
response and emphasize the importance of compliance. Hence, eight total physician
visits and five psychotherapy visits are associated with this path. Conversely, Path 4
assumes the patient relapsed despite full compliance. Therefore, therapy is changed to
paroxetine (Paxil) and full compliance is again assumed. A full 26 weeks of fluoxetine,
24 weeks of trazodone (for the first six months), and 26 weeks of paroxetine are required
in Path 4.
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Paths 5, 6, and 7 are virtually the same as 2, 3, and 4 respectively. However, since these
paths assume no treatment is required for side-effects, the cost of an additional physician
visit is not present, nor is the cost of trazadone. All else remains the same.
The last path in the fluoxetine arm, 8, represents treatment failures. As discussed
previously, patients failing to respond by week four to fluoxetine are switched to
paroxetine (Paxil). It is assumed that these patients are more treatment resistant and
will require a higher dose of paroxetine. Therefore, the cost of 30 mg Paxil was used in
this path as opposed to the mix of 75% of the 20 mg daily cost and 25% of the 30 mg cost
being used.

All assumptions hold true for the St. John's Wort arm of the model. The main difference
is the omission of the side-effect treatment outcome. This was omitted due to the type of
adverse effects reported. The most commonly reported effects such as headache and
gastrointestinal upset do not require treatment with a prescription medication. Rather
they are usually self-limiting and/or managed with over-the-counter medications.

The only cost difference in this arm is that of the extract itself, which would be
substituted for the cost of fluoxetine in Paths 1, 5, 6, 7, and 8. To remain consistent
across treatment groups, a similar assumption was applied to the cost of the extract.
Based on the expert panel’s estimate of 25% of patients requiring a higher dose of
fluoxetine, this condition was placed on St. John's Wort. Cost of therapy was estimated
from 75% of the average cost of a 30-day supply of 300 mg capsules three times a day
plus 25% of 600 mg capsules three times a day.
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ANALYTIC STRATEGY
A total cost associated with each drug was evaluated without respect to effectiveness
data. Expected cost-effectiveness was then calculated for each arm of the decision tree
by folding back the tree. Once the base case analysis was performed, sensitivity analyses
was performed on several variables. A one-way sensitivity analysis was performed on
the response (success) rate of fluoxetine since there was not consensus in the literature on
the value of this variable. The probability of successful treatment for the fluoxetine arm
was varied from 40% to 77%. These values were derived from the published metaanalyses identified in the literature search. Similarly, the response rate for St. John's
Wort was also varied from 43% to 76%.

Given that acquisition cost usually plays a large role in choice of therapy, the cost of
fluoxetine as well as St. John's Wort was analyzed to determine at what cost, if any, a
difference in cost-effectiveness may be seen. The other variables that were tested were
those that were not well supported in the literature nor well defined by the expert panel.
These include rates of discontinuation, relapse/remission, and non-compliance for both
therapies. A threshold analysis was reported for variables that proved to be important in
terms of its affect on the overall result. Two-way sensitivity analyses were also
conducted to better analyze the effect of changing the value of multiple variables.
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CHAPTER 4
RESULTS
INTRODUCTION
A cost-effective analysis was performed based on the principles of decision analysis to
determine optimal choice of therapy for treatment of mild to moderate depression. The
perspective of the study is that of a third-party payer and takes into account direct
medical expenses incurred by the payer in the outpatient setting. The costs and outcomes
of fluoxetine and St. John’s Wort are being compared by means of a decision tree model
that typifies clinical management of the disease. This model was developed based on the
results of the survey (Appendix A) of an expert panel of practitioners. The results of
each objective are presented below.

TOTAL COST OF THERAPY

Objective A. Calculate the expected cost associated with the treatment of mild to
moderate depression using fluoxetine at the initial dose of 20 mg
once a day.

The total cost for each pathway using fluoxetine in the decision tree is presented in Table
4.1. The least costly pathway in the fluoxetine arm ($1,820/patient) is represented by a
successful response that does not require treatment for side effects followed by remission
requiring six months more of maintenance therapy. The possibility of a successful
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response requiring treatment for side effects followed by a relapse requiring a change of
drug therapy is the most costly for fluoxetine ($2,248/patient).
Table 4.1 Total costa of care for fluoxetine
Fluoxetine
PATH PATH PATH PATH
1
2
3
4
MD eval
$145
$145
$145
$145
(1)
(1)
(1)
(1)
MD f/u
$85
$85
$85
$85
(6)
(6)
(7)
(7)
Psych eval
$115
$115
$115
$115
(1)
(1)
(1)
(1)
Psych f/u
$75
$75
$75
$75
(4)
(4)
(5)
(5)
TSH
$25
$25
$25
$25
(1)
(1)
(1)
(1)
b
Fluoxetine
$15.5 $15.58 $15.58 $15.58
8 (4)
(52)
(44)
(26)
b
Trazodone
$3.50 $3.50 $3.50
$3.50
(2)
(50)
(34.5) (24)
Paroxetineb $19.3 $19.37 $19.37 $19.37
7 (48) (0)
(0)
(26)
TOTAL
$2094 $2080 $2061 $2248
a

PATH
5
$145
(1)
$85
(5)
$115
(1)
$75
(4)
$25
(1)
$15.58
(52)
$3.50
(0)
$19.37
(0)
$1820

PATH
6
$145
(1)
$85 (6)

PATH
7
$145
(1)
$85 (6)

$115
(1)
$75 (5)

$115
(1)
$75 (5)

$25 (1)

$25 (1)

$15.58
(44)
$3.50
(0)
$19.37
(0)
$1856

$15.58
(26)
$3.50
(0)
$19.37
(26)
$2079

PATH
8
$145
(1)
$85
(6)
$115
(1)
$75
(5)
$25
(1)
$15.58
(4)
$3.50
(2)
$19.53
(48)
$2177

Dollar value is the cost per unit; Number of units incurred is in parentheses.
Drug costs represent cost per week of therapy.
MD eval=initial physician evaluation; MD f/u=physician follow-up visits; Psych eval=initial psychotherapy
evaluation; Psych f/u=psychotherapy follow-up visits; TSH=thyroid stimulating hormone level
b

Objective B. Calculate the expected cost associated with the treatment of mild to
moderate depression using St. John's Wort at the initial dose of 300
mg three times a day.

The total cost for each pathway using St. John's Wort in the decision tree is presented in
Table 4.2. Similar to fluoxetine, the least costly pathway in the St. John's Wort arm
($1,201/patient) is represented by a successful response followed by remission requiring
6 months of maintenance therapy. However, the most costly pathway differs from that of
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fluoxetine. For St. John's Wort, the pathway representing treatment failure requiring a
change of drug therapy is the most costly possibility ($2,122/patient).

Table 4.2 Total costa of care for St. John's Wort
St. John's Wort
PATH 9
PATH 10
MD eval
$145 (1) $145 (1)
MD f/u
$85 (6)
$85 (5)
Psych eval
$115 (1) $115 (1)
Psych f/u
$75 (4)
$75 (4)
TSH
$25 (1)
$25 (1)
b
Extract (St. John's Wort) $3.68 (4) $3.68
(52)
b
Paroxetine
$19.37
$19.37
(48)
(0)
TOTAL
$2039
$1201
a

PATH 11
$145 (1)
$85 (6)
$115 (1)
$75 (5)
$25 (1)
$3.68
(18)
$19.37
(26)
$1740

PATH 12
$145 (1)
$85 (6)
$115 (1)
$75 (5)
$25 (1)
$3.68
(26)
$19.37
(26)
$1769

PATH 13
$145 (1)
$85 (6)
$115 (1)
$75 (5)
$25 (1)
$3.68 (4)
$19.53
(48)
$2122

Dollar value is the cost per unit; Number of units incurred is in parentheses.
Drug costs represent cost per week of therapy.
MD eval=initial physician evaluation; MD f/u=physician follow-up visits; Psych eval=initial psychotherapy
evaluation; Psych f/u=psychotherapy follow-up visits; TSH=thyroid stimulating hormone level
b

COST-EFFECTIVENESS
Objective C. Assess the overall cost per successfully treated patient (costeffectiveness) of St. John's Wort.
Objective D. Assess the overall cost per successfully treated patient (costeffectiveness) of fluoxetine.
Objective E. Assess the incremental cost-effectiveness of St. John's Wort
compared to fluoxetine.

When the tree is rolled back, the base case analysis reveals St. John's Wort to be the most
cost-effective treatment for mild to moderate depression over a period of one year based
on a third party perspective (Appendix B). The one-year cost per successfully treated
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patient with St. John's Wort is $1,788 compared to $2,040 with fluoxetine . This results
in an incremental cost-effectiveness ratio of $252 per patient per year.

SENSITIVITY ANALYSES

Objective F. Assess the robustness of the findings by performing sensitivity
analyses.

The robustness of this result was tested by performing several univariate and multivariate sensitivity analyses. Variables that were not well represented in the literature, had
a wide range of published values and those for which consensus was not reached by the
expert panel were chosen to analyze. In total, a two-way sensitivity analysis and 12 oneway sensitivity analyses were performed on the following variables for each therapy:
probability of success (measured by response rate), cost of therapy, probability of
remission, probability of relapse from noncompliance, probability of agitation as a sideeffect, and probability of discontinuation.

The one-way sensitivity analysis on probability of success with fluoxetine was performed
by varying the success rate from 40% to 77% and maintaining St. John's Wort at 64%
success rate. This range was chosen based on the highest and lowest reported values in
the literature. The results of the analysis illustrate that St. John's Wort remains more
cost-effective than fluoxetine at any value in the given range (Graph 4.1). In fact, the
slope of the line depicting the expected value for fluoxetine suggests that even success
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rates greater than 77% would not change the expected value enough to make fluoxetine a
better (more cost-effective) choice than St. John's Wort.

Graph 4.1

The results were then tested in a one-way sensitivity analysis based on the value of St.
John's Wort success rate. This value was ranged from 43% to 76% based on published
rates in the literature while keeping fluoxetine’s success rate constant at 63%, the base
case estimate. The results of the base case analysis were not affected by changing the
rate of success for St. John's Wort (Graph 4.2). At all values, St. John's Wort was shown
more cost-effective than fluoxetine. Hence, the results are very insensitive to the actual
response rate of each therapy.
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Graph 4.2

The analysis was then repeated to determine if a lower success rate would affect the
results. The analysis was performed for the range of 25% to 76% while maintaining
fluoxetine at 63% (graph 4.3). Once again, the expected cost of St. John's Wort remained
lower than fluoxetine making it the more cost-effective alternative.
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Graph 4.3

Cost plays a large role in the initial choice of therapy. Fluoxetine’s patent recently
expired, and several generic products are currently marketed at substantially lower prices
than Eli Lilly’s brand of Prozac. Given that this variable has such an integral role in
choice of therapy in clinical practice, it was of interest to test its effect on total cost of
care as modeled in the decision tree. A sensitivity analysis was performed on both the
cost of fluoxetine and the cost of St. John's Wort.

The first analysis tested the effect of varying the cost of a one-week supply of fluoxetine
from $4.67 ($20.01 per 30-day supply) to $31.08 ($133.11 per 30-day supply) while
maintaining the weekly cost of $3.68 for St. John's Wort. The range for fluoxetine's cost
was chosen to represent the likely cost for the generic product once competition drives
down the price and the highest probable cost for the brand product. Results of this
analysis (Graph 4.4) demonstrate that drug acquisition cost does affect the overall costeffectiveness of therapy. In this analysis, the most cost-effective therapy changes from
St. John's Wort to fluoxetine once the cost per week of fluoxetine is below $5.40. At the
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threshold value of $5.40 per week of fluoxetine, cost-effectiveness is equivalent,
rendering the decision-maker indifferent to the alternatives.

Graph 4.4

A one-way sensitivity analysis was repeated on the cost of a one-week supply of St.
John's Wort (Graph 4.5). The analysis held fluoxetine's weekly price constant at $15.58
while St. John's Wort was varied over the weekly cost range of $1.35 ($5.79 per 30-day
supply) to $20.00 ($85.71 per 30-day supply). These figures represents those obtained
from 6 different brands sold by various retailers including GNC, Vitamin World, and
Brooks Pharmacy located in Connecticut. The resultant graph depicts a point of
indifference where both options are equally cost-effective. At any cost above $15.80 per
week for St. John's Wort, fluoxetine is a more cost-effective alternative. Both graphs 4
and 5 illustrate that drug acquisition cost plays an important role in the overall cost of
therapy and the results of the base case analysis are relatively sensitive to this variable.
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Graph 4.5

Given that the cost of either therapy affects the decision made in this model, a two-way
sensitivity analysis was performed to better evaluate the effect of drug cost on choice of
therapy. Graph 4.6 represents the effect of cost of therapy on the optimal decision. The
graph is divided into two sections. The light gray section represents all costs for each
therapy that result in St. John's Wort being more cost-effective while the dark area in the
bottom right side of the graph depicts all costs that yield fluoxetine as the most costeffective therapy. At the lowest cost over which both St. John's Wort and fluoxetine were
varied, St. John's Wort remains the most cost-effective choice. However, at the highest
cost for St. John's Wort, it is only the best choice if fluoxetine’s cost is more than
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approximately $18.00 per week. Once fluoxetine drops below 18.00 per week, St. John's
Wort is no longer the most cost-effective option at that price.

Graph 4.6

>Bottom of graph
>Top of graph

The next variable tested was the probability of remission. First, the value for St. John's
Wort was tested over the range of 20% to 65% while fluoxetine remained constant at
49% (Graph 4.7). For all possible values, the outcome did not change. Total expected
cost of therapy remained lower for St. John's Wort than fluoxetine.
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Graph 4.7

The same analysis was done on the probability of remission for fluoxetine (Graph 4.8).
The rate was ranged from 35% to 90% while St. John's Wort remained constant at 40%.
Again, no difference was detected in this analysis. Although the pathway leading to
remission for fluoxetine was the least costly, the rate of remission had no bearing on the
overall results.
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Graph 4.8

Probability of relapse due to noncompliance was also tested to determine how robust the
results were to a change in this variable (Graph 4.9). The rate was varied from 10% to
85% for St. John's Wort, and fluoxetine’s rate remained constant at 20%. The expected
value of cost per successfully treated patient remained virtually unchanged. For all
values in the range, the expected value for St. John's Wort was between $1,780 and
$1,800 per successful treatment.
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Graph 4.9

The analysis was repeated for fluoxetine ranging the rate from 5% to 40%, keeping St.
John's Wort at 40% (Graph 4.10). Again, this resulted in little change to the expected
value of fluoxetine. Neither analysis resulted in a change in optimal decision.

Graph 4.10
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The next variable to be tested was the discontinuation rate for both therapies. St. John's
Wort was varied from 2% to 52% (Graph 4.11). The high-end was based on four times
the maximum rate published in the literature, to try and determine if very liberal
estimates would affect the overall result. The low-end represents the discontinuation rate
for placebo, estimating that this would be the lowest possible probability. Even at the
highest value of 52%, the expected value for St. John's Wort is well below fluoxetine.

Graph 4.11

Fluoxetine’s discontinuation rate was then varied while keeping St. John's Wort rate
constant (Graph 4.12). Fluoxetine was tested over the range of 2% to 20%. The high end
of the range was determined by the expert panel as the frequency of discontinuation
secondary to side-effects. Responses for this estimate varied however, with 20% being
the highest and the most frequently reported. The expected value for fluoxetine
fluctuated by less than $10 over the given range, remaining well above the expected
value of St. John's Wort.

104

Graph 4.12

The last variable tested was the probability estimate of the percentage of patients on
fluoxetine who would require treatment for the side-effect of agitation. This variable was
tested over the range of 2% to20% (Graph 4.13). Cost-effectiveness for fluoxetine
changed only slightly over the range of probabilities. Hence, the results were not
sensitive to this variable.

105

Graph 4.13

Overall, the results of the base case analysis remained stable and relatively insensitive to
changes in most of the variables in the model. Even after the range for response rate was
expanded to include the low end of 25%, the results did not change. However, cost of
therapy did prove to be an important predictor of the optimal choice of therapy.
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CHAPTER 5
DISCUSSION AND CONCLUSIONS

INTRODUCTION
Depression is a debilitating illness that affects approximately 10% of the American adult
population yearly. The devastation it creates is manifested in loss of self-worth and
diminished quality of life, loss of productivity, earnings, and in many instances, a loss of
social contact. The burden of illness translates into millions of dollars expended on
treatment of the social and physical dysfunction that defines the disease.

As healthcare costs continue to skyrocket and financial resources dwindle, both
healthcare providers and payers struggle to contain costs while maintaining quality of
care. One strategy that many providers of healthcare such as Health Maintenance
Organizations (HMO) use as a method of cost-containment is formulary management.
This process involves critically evaluating the therapies that are currently marketed and
limiting those included on the prescription drug benefit plan to therapies that meet certain
criteria.

Ultimately, drugs that deliver a large benefit at a low cost are desired. However, as
newer therapies enter the market, they usually come with a high price. Therefore, it is
imperative that these therapies be critically evaluated to determine their incremental
benefit over current therapies. As such, more companies are turning to economic analyses
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to provide both clinical and economic outcome data to aid in formulary decision-making
(Langley, 1996).

St. John's Wort, though not a novel therapy, has within the last several years gained in
popularity in the United States as an antidepressant. Through analysis in multiple clinical
trials, the herb was demonstrated to be an effective treatment for patients with mild to
moderate depression. However, because these evaluations were conducted in rather
"sterile" conditions, as required in randomized controlled trials, it is difficult to predict
how patients will respond in clinical practice. Additionally, since most of the studies
compared the herb to tricyclic antidepressants, more meaningful data would come from
comparisons to selective seratonin re-uptake inhibitors (SSRIs), as they continue to
dominate the prescription antidepressant market. Because St. John's Wort is relatively
inexpensive compared to many of the prescription alternatives, answering these questions
provide valuable information to payers of healthcare services.

EXPLANATION OF THE MODEL
To shed light on this important clinical and economic matter, a cost-effective evaluation
was conducted from a payer's perspective using decision analysis to model the outpatient
treatment of mild to moderate depression. St. John's Wort was tested against one of the
more frequently prescribed antidepressants, fluoxetine, in an effort to maximize external
validity. Fluoxetine was chosen as a representative of the class SSRIs. In turn, results of
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the study are more applicable to today’s outpatient population as SSRIs continue to be
among the top ten most prescribed therapeutic classes (Pink Sheets, 2002).

A decision tree was created based on clinical management of depression as described by
a panel of experts experienced in the diagnosis and treatment of depression. This is a
common practice in the construction of clinical and financial outcomes of disease state
management. The panel consisted of two psychiatrists, one pharmacist who specialized
in psychiatry, and three primary care physicians. Although psychiatrists may be thought
of as the experts in the treatment of depressive disorders, patients are more often treated
by their primary care physicians (Brown, 1997), and therefore family practitioners
provide a better reflection of clinical practice.

The practitioners aided in determining and validating the main outcomes of treatment:
remission, relapse, and discontinuation of therapy. Associated with those outcomes are
the need to treat side-effects, convenience/compliance issues, dosage adjustments, and
the need to change drug therapy. As described in the results of the panel survey, there are
slight variations in outpatient practice management among practitioners. However,
overall management did not vary significantly and closely followed the recommendations
of the American Psychiatric Association.

All agreed that SSRIs were the most frequently prescribed agents and were thought to be
effective for most patients. Most practitioners agreed that if a patient failed to respond to
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one SSRI, they would switch them to another drug in that class. This practice is
supported by literature that shows SSRIs are equally efficacious; hence, choice of therapy
depends mainly on the patient's past medical history, chance of adverse effects,
preference, potential compliance problems, and financial factors. Because this study was
conducted from the perspective of a third party payer with the objective of determining
cost-effectiveness of St. John's Wort compared to standard antidepressant therapy, the
choice of no pharmacological treatment was not included in the model.

In this study, St. John's Wort was shown to be a more cost-effective therapy than
fluoxetine, saving the insurance company approximately $252 per patient per year.
However, varying the cost of St. John's Wort and/or fluoxetine changes this result. Once
fluoxetine's cost drops below $23.66 per month, it becomes the more cost-effective
choice of therapy with St. John's Wort cost held constant at $15.77 per month. Cost
estimates were based on published average wholesale prices (AWP). However, this
actually represents charges to the third party payer instead of actual cost to the payer.
Typically, insurance companies reimburse pharmacies a certain percentage of the AWP
plus a dispensing fee. Actual rates depend on the individual providers, the contracts they
have with the pharmacies, and the formulary plan provided to members.

The range over which the sensitivity analysis for drug cost was conducted was obtained
by using the highest average AWP for brand Prozac and applying the assumption that
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25% of patients require 40 mg while 75% are maintained on 20 mg. This yielded a price
per week of $31.08 or $133.11 for a 30-day supply.

The average AWP for generic fluoxetine as of Decemember 2002 was $2.67 per 20 mg
tablet and $5.32 per 40 mg tablet. Taking 25% of the average generic AWP for the
lowest dose of fluoxetine (20 mg) yielded the low end of the cost range. This equation
was used to estimate reimbursement rates or costs to the third party payers, as opposed to
charges. In doing so, the average cost to the payer for a 30-day supply of generic
fluoxetine is $20.03 or $4.67 per week. Thus, even the lowest cost estimate for generic
fluoxetine is higher than the breakeven point for cost-effectiveness compared to St. John's
Wort as illustrated in Graph 4.6.

Competition among the generic manufacturers is likely to drive the price down for
fluoxetine. In other words, as the number of generic manufacturers of fluoxetine
increase, the AWP will likely fall, with concurrent diminishes in reimbursement rates.
Similarly, the price of St. John's Wort has decreased over the last several years and is
expected to continue to fall due to a supply surplus combined with a slight decrease in
demand (Ferrier, 2002). As St. John's Wort's price decreases, fluoxetine's cost must get
substantially lower for it to be the most cost-effective alternative as demonstrated in
Graph 4.6.
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Other than cost of therapy, no other single variable significantly affected the base case
results. This may be due to the fact that the primary management of this disease, mild to
moderate depression, is drug therapy. Unlike more severe forms of depression that often
require hospitalization and frequent physician visits, this disorder is primarily managed in
the outpatient setting. Additionally, insurance restrictions typically limit patients’
utilization of healthcare resources for mental health. It is not surprising that drug therapy
remains the cornerstone of management and therefore, an important predictor of overall
cost of treatment.

Response to therapy was initially thought to be a strong predictor of overall costs. The
degree of effectiveness of fluoxetine from the clinicians’ perspective varied from a 50%
success rate to a 70% success rate. This coincided closely to the range of 40% to 77%
published in the medical literature. A one-way sensitivity analysis was conducted over
the range of 40% to 77% using the maximum and minimum values obtained for
fluoxetine. The same was done with the success rate of St. John's Wort, varying it from
43% to 76% based on meta-analysis. These analyses demonstrated that the probability of
success is not an important determinant of cost-effectiveness in this model.

The National Institute of Mental Health sponsored a $4 million study conducted at Duke
University that assessed the use of St. John's Wort versus sertraline or placebo and
focused on the treatment of severe depression (Hypericum Trial Depression Study Group,
2002). The results of this study failed to support use of either agent. Consequently,
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many questions instead of answers arose from this trial. Many speculated that the
therapies failed to demonstrate efficacy due to the relatively treatment-resistant
population in whom they were tested. The study population had a diagnosis of
depression for a minimum of two years.

Several other estimates were not well documented in the literature, and expert opinion
varied substantially. The panel estimated the percentage of patients that required
treatment with trazodone to be less than 1% to a high of 20%. This may depend on the
characteristics of the patient population each individual practitioner treats. One
practitioner may see a disproportionate number of patients with multiple comorbid
conditions who may be more sensitive to the drug's adverse effects than otherwise
healthy patients. Another reason could stem from some practitioners being more acutely
aware of side-effects than others.

In any case, this was one of the possible outcomes identified by the providers and needed
to be included in the model. Therefore, estimates were based on randomized clinical
trials instead of expert opinion due to the disparity in responses. However, the estimate
of 10% of patients requiring treatment for anxiety may have been greatly underestimated.
One study found that 35% of patients on SSRIs received either an anxiolytic or sedative
concurrently based on claims data in a California Medicaid population (Rascati, 1995).
Fifteen percent of these prescriptions were for once-daily sedatives implying treatment of
sleep disturbances.
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This pathway assumed an additional physician visit would be required to manage the
side-effect and that trazodone would be continued for the duration of treatment. Despite
this, the sensitivity analysis from this study demonstrated that changing the value of this
variable resulted in only minor changes to the expected cost-effectiveness of therapy.
Therefore, in this model, treatment of side-effects is not a strong predictor of overall costeffectiveness. This is probably due to the relative low cost of trazodone. In this model, it
was estimated to cost approximately $3.50 per week or $15.00 per month based on
average AWP.

Other variables for which there was a lack of information included remission, relapse and
compliance rates. Therefore, large ranges were chosen to gauge the effect on the
expected cost of therapy. The rate of remission chosen for fluoxetine was based on a trial
that studied patients in a natural setting and measured a rate of remission of 49% at six
months. This may seem low based on several other decision analytic models. However,
testing its affect over the range of 35% up to 90% did not change the results of the study.

Similarly, compliance rates did not seem to affect outcome of cost-effectiveness.
Compliance, defined as taking 69% of the prescribed medication, was extropolated for
fluoxetine based on a study comparing compliance rates of different regimens of
antihypertensive medications. Once-daily regimens were associated with an 84% rate of
compliance while thrice-daily regimens fell to 59%. Fluoxetine, though much better
tolerated in clinical trials than tricyclics, still has a number of bothersome side-effects
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such as agitation, headache, nausea, sexual dysfunction, and weight gain. Hence, noncompliance was assumed to be 20% as compared to 16% found for once-daily regimens.
This figure was ranged from 5% to 40% but failed to produce significant differences in
results. Rates of non-compliance for St. John's Wort were also extrapolated from this
study and estimated to be twice that of fluoxetine given its thrice daily regimen, which is
similar to the compliance rate of the thrice-daily antihypertensive regimens.

Though St. John's Wort yielded a lower cost per successfully treated patient, the
difference was only $252 per patient per year. Additionally, as previously mentioned,
this is highly dependant on the cost of therapy used in the model. However, it is clear
that St. John's Wort is a reasonable alternative to fluoxetine in this study. It may be a wise
choice for pharmacy benefit providers to add the herb to their formulary. Although
patients have the option of taking the extract on their own given its availability over-thecounter, in many instances they are not under the guidance of a physician and may not
take the proper dose. Offering insurance coverage may increase the likelihood that
patients will take the herb on the advice of their healthcare provider and will more likely
follow the regimen used in clinical trials. It may also lend credibility to the extract in the
eyes of patients and healthcare professionals.

The concern over quality and reliability of these herbal products still remain a primary
factor among practitioners, patients, and providers alike. Can the products prescribed be
trusted to contain the needed ingredients and the quantity required to achieve a clinical
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response? How can one ensure that the product they prescribe will contain exactly what
the label claims? The American College of Physicians (ACP) and American Society of
Internal Medicine (ASIM) guidelines include the statement that St. John's Wort is not
approved by the Food and Drug Administration (FDA) and warn that products may vary
from those tested in clinical trials.

Despite the results of several randomized clinical trials and the results of this study, many
practitioners may still be unwilling to "prescribe" a non-FDA approved herbal. Although
it is common for patients to self-medicate with herbals without their doctor's knowledge,
let alone their recommendation, prescribers may be concerned with legal ramifications of
prescribing these products, should an adverse event occur. In contrast, prescribers often
use medications for non-FDA approved indications when strong clinical evidence exists.
Many pharmaceutical manufacturers are aware of this and forego the costly process of
gaining FDA approval. One example is the use of aspirin for prevention of myocardial
infarction in high-risk patients. Based on extensive literature, prescribing aspirin for this
indication has become standard of therapy. However, it is not a FDA-approved
indication. In this regard, herbal manufacturers are unlikely to pursue FDA approval
since consumers are already using their products.

Hyperforin is generally recognized as the primary active constituent of St. John's Wort.
However, hyperforin is very unstable and rapidly degrades in the presence of light or
oxygen. Therefore, it is rarely used to standardize products. Rather, hypericin is
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commonly used for standardization. Valid assays have been developed to accurately
determine hypericin and hyperforin content without compromising integrity using highperformance liquid chromatography. This method was used to assess the content of
several brands of Hypericum (de los Reyes, 2002). Some of the products were found to
have either lower or higher amounts of hypericins than claimed on the label. This also
has lead to hesitation in using or recommending use of this as well as other
nutraceuticals.

Product quality is dependent on a number of different factors such as crop variability due
to growing conditions, contamination, and manufacturing practices. In vitro culture
technology has been developed to solve this problem of standardization. The technique
allows for production in a sterile, standardized condition ensuring products are consistent
and constituents are precise, though it may be cost prohibitive at this stage. There is
currently considerable variability among the products marketed in terms of constituent
amount and standardardization practice. Consequently, it is recommended that the FDA
through the Diet Safety Health and Education Act, require more stringent regulation on
the manufacturing of dietary supplements. Standardization protocols including specific
assays should be required to ensure quality. Strict regulatory controls on manufacturing
practices, initiated in 1994, are still years from being implemented. Until this is law, one
proposal is to use the brands that were tested in the clinical trials.
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One brand in particular, LI 160, manufactured by Lichter Pharmaceuticals in Germany
and marketed under the brand name Kira (Jarsin in Germany), has been tested in
numerous clinical trials. It is however, one of the more expensive brands found on the
market. It retails at $20.58 for a 30-day supply, which is still substantially lower than
fluoxetine's average retail price. Nonetheless, this product provides some assurance that
the actual contents match the label.

STRENGTHS OF THE STUDY
There are currently no published data regarding the cost-effectiveness of St. John's Wort.
However, this study has provided information to third party payers to aid in formulary
management strategies. By employing the method of decision analysis, insurance
providers can make more informed decisions under conditions of uncertainty. Decision
analysis allows one to understand the impact that uncertainty has on the final result, in
this case, cost-effectiveness of the drug.

Unlike a randomized controlled trial, decision analysis can be more reflective of realworld conditions by amassing clinical judgement and clinical trial results to portray the
likely outcome of using St. John's Wort over fluoxetine. For example, in randomized
controlled trials involving fluoxetine, patients are randomized to active treatment, usually
consisting of fluoxetine given in a dose of 20 mg once daily. Dosage adjustments are
rarely, if ever, allowed in the protocol. However, as described by the expert panel, it is
common to increase the dose of fluoxetine if an adequate response is not achieved. The
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model in this study incorporated dosage increases in the cost of therapy and modeled the
treatment of depression based on clinical practice as described by the providers of care.
Additionally, according to previous studies, depression is often managed differently than
what has been recommended. Frequently, patients are prescribed inappropriate doses
and/or for inadequate durations of time (Ormel, 1991;Katon et al, 1992). Therefore, it
was important to use information obtained directly from the healthcare practitioners that
most often provide care to these patients, instead of relying strictly on consensus
guidelines.

This study has provided a model for healthcare providers and payers to utilize in making
policy and individual patient decisions. Providing estimates and ranges along with the
sources of data used allows decision-makers to determine the relevance of the results to
their patient or customer population. This is referred to as the "transparency" of the
model. Additionally, the sensitivity analyses conducted test the robustness of the data
and better explain the impact various inputs have on the final result.

Another strength of the study is that it provided information on the cost-effectiveness of
St. John's Wort. Prospective studies such as pragmatic or naturalistic trials provide
excellent data in "real-world" conditions and are therefore generalizable to the population
likely to be affected. On the other hand, they are usually very costly and time
consuming. Given the rising costs of pharmaceuticals and the grave need to control
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spending, healthcare decision-makers need information quickly and most likely do not
have the resources to conduct such evaluations.

ASSUMPTIONS AND LIMITATIONS
The analysis was conducted based on a number of assumptions. Patients failing to
respond to initial treatment (either from discontinuation, relapse, or initial failure) were
assumed to respond to the second course of therapy and therefore, the full cost of the
second drug therapy was incurred along with the associated number of physician and
therapist visits. In real world conditions, however, patients go through the same cycle of
having a probability of responding to or failing the secondary therapy. To simplify the
model, this probability was set at 100%. Therefore, total cost of therapy for both arms of
the decision tree may be underestimated. However, since the objective of the study was
to measure the overall difference in cost-effectiveness, precise cost estimates of variables
such as physician visits are not crucial if the same estimates are used in both treatment
arms of the decision tree.

The model assumes that all treatment failures are switched to paroxetine (Paxil) except
for patients initially treated with fluoxetine who relapse due to noncompliance. These
patients would continue another six months of fluoxetine given that it is a once daily
regimen and paroxetine would offer no advantage in this respect. Treatment failure or
relapse also implies the number of physician visits increases from six to seven per year.
Similarly, psychotherapy visits increase from five to six per year. The reason for this is
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that it is presumed that patients in a state of depression (failure to respond to therapy) are
more likely to utilize healthcare services than those who are being successfully treated by
medications.

Psychotherapy was included as an important component of the treatment model. This
was based upon responses from the expert panel stating that most would refer a patient to
a therapist in addition to prescribing drug therapy. It is important to note that the panel
members were all from an urban university setting where there is access to trained
psycologists and psychiatrists. However, in more rural settings, access is greatly limited.
Therefore, the cost of psycotherapy visits would not apply and overall cost of care may
be reduced. On the other hand, response rates may decrease and relapse rates may
increase resulting in an overall increase in cost of care. In any case, overall results are
difficult to predict.

Treatment for side-effects due to fluoxetine was limited to trazodone. This was described
as the most frequently prescribed medication for treatment-related side-effects due to
fluoxetine. However, it is possible that other medications may be required, though they
were not represented in this model. Patients on St. John's Wort were assumed not to
require any additional medical treatment for adverse effects. Side-effects from the herb
were assumed to be amenable to over-the-counter medications for which third-party
providers would not bare the costs. This seems reasonable since large observational
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studies on St. John's Wort have failed to demonstrate any significant side-effects
requiring treatment.

Direct costs of medical care were based on charges obtained from physician offices in
Connecticut. These costs may not be representative of other areas of the country, nor are
they representative of the public health sector. Though total cost of care may be over or
underestimated, as pointed out before, these costs did not differ between therapies and
therefore will not affect choice of therapy based on incremental cost-effectiveness. On
the other hand, cost of therapy, does make a significant difference on the results.
Acquisition cost for each therapy was based on average wholesale price (AWP) or prices
obtained from retailers located in southeastern Connecticut. These prices may differ
significantly from those found outside of Connecticut. The model also did not include
inpatient cost of care. It was assumed that patients with mild to moderate depression
would not require hospitalization for care of the illness.

It is important to point out that the survey of the expert panel was conducted in 1998
when fluoxetine was only available as the brand product, Prozac. Responses may vary
somewhat today based on its availability as a generic product. Factors such as patients'
and practitioners' preference for brand products may play a role in prescribing the drug
and how effective it is perceived to be. Additionally, the panel had no experience in
prescribing St. John's Wort. Only a few of them had any prior knowledge of the herb.
Therefore, all estimates of effectiveness were culled from the literature.
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In many circumstances, estimates were based on short-term trials (six to eight weeks) and
extrapolated to the one-year cycle of the model. Discontinuation rates, for instance, were
obtained from six-week trials, but rates of discontinuation differ over time. Multiple
studies were needed to find all the estimates required in the model, representing a rather
heterogeneous population. In one way, this aids in generalizability; however internal
validity is diminished. Separately, the studies tested only individuals with mild to
moderate depression. Therefore, results can only be generalized to this population.

Analysis of the study was limited to a period of one year. Therefore, subsequent relapses
that may occur are not accounted for in this model. However, this may be less relevant to
third party payers due to possible attrition of members. This is one reason many
insurance providers don't cover preventative therapy. The company doesn't retain the
member long enough to reap the future benefits of decreased cost of care. Therefore,
cost-effectiveness of one year of therapy may be more practical in terms of making policy
decisions.

The perspective of this study was that of a third party payer, such as a health maintenance
organization (HMO). Costs such as out-of-pocket expenses and outcomes such as lost
wages or productivity were not accounted for in the model as they would not be incurred
directly by the HMO. In general, it has been recommended to conduct cost-effective
analyses from the societal perspective. However, as information is not always readily
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available, this can be an arduous task. Additionally, results of such a trial may be
difficult to interpret for the purposes of this study.

SIGNIFICANCE OF THE STUDY
Depression is a devastating illness that has significantly impacted the public both
economically and physically. There is a great need to critically evaluate the potential of
any new therapy that may prove to be of benefit. St. John's Wort became increasingly
popular in the United States as a mood stabilizer in the mid-1990s. Although it is still
among the top selling herbal products, the fervor has calmed somewhat since then. This
may be due to media attention in the past year questioning its use in depression or just
representative of the overall decline in the economy. Add to this the lack of regulation on
advertising and marketing of herbal products and it underscores the importance of critical
evaluation of both cost and clinical outcomes.

It is clear the public needs an unbiased assessment of these products evaluated against the
standard of care. This study serves that purpose. It provides relevant information to
patients and providers of healthcare in helping to better allocate limited resources. The
analysis serves as an integration of expert opinion and clinical data into a model of
current clinical practice. The decision tree developed may also be used as a model to
assess future treatment modalities.
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CONCLUSIONS
It is evident that St. John's Wort represents a viable alternative to fluoxetine and most
likely to other prescription antidepressants based on the wealth of clinical information
available and supporting data on its cost-effectiveness from this study. The Agency for
Health Care Policy and Research recognizes St. John's Wort as a rationale therapy in the
treatment of mild depressive disorder. The ACP and ASIM guidelines also include St.
John's Wort as a treatment option for short-term treatment of mild acute depression.
Given this, healthcare providers should strongly consider adding it to the armamentarium
of drugs included in their prescription drug benefit plan.

A variety of drugs should be available to patients and healthcare practitioners in order to
tailor therapy based on individual circumstances such as tolerability, compliance,
comorbid illnesses, possible drug interactions, and allergies. By offering St. John's Wort
on drug benefit plans, third party payers may realize long-term cost savings. Initial costs
may increase if patients who would normally not seek medical attention begin to utilize
medical services in order to get insurance coverage for the herb. However, in the long
run, the increase in medical utilization may actually decrease overall costs of care. If
patients with more mild forms of the disease are treated under the care of a physician and
take the product according to recommendations, then potentially more patients will be
adequately treated and ultimately use fewer healthcare resources.
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The overall difference in savings in this study is not dramatic, but it is consistent with
what other studies comparing antidepressant therapies have found. Adding St. John's
Wort to a drug formulary will offer patients a safe and effective alternative to prescription
products. This addition may not offer huge financial savings short-term, but if utilized
may help calm the rate of spending the healthcare system has experienced. However,
until the FDA has tighter controls on the manufacturing of St. John's Wort products or a
prescription status product becomes available, prescribers may still tend to shy away
from prescribing this herbal remedy, regardless of cost-effectiveness.

FUTURE RESEARCH
There is a need for additional studies such as this one to be conducted. As mentioned
previously, it is generally recommended to conduct economic evaluations from the
perspective of society to capture all costs and consequences of the treatment choice.
This, of course, would require an intense amount of resources in terms of both time and
money. Although this is no easy task, assessing quality of life parameters may be quite
possible. Obtaining utility values would enable one to conduct cost-utility analyses that
could be done from either the patient or the payers perspective. It would be of great use
to have information regarding patients' quality of life on this herbal remedy compared to
standard treatments such as the SSRIs. Additionally, studies that focus on newer
treatments like mirtazapine (Remeron) would also be of great benefit.
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Long-term studies on St. John's Wort are still needed to determine efficacy past the acute
phase of treatment. This would be best accomplished through a randomized controlled
trial that tested both placebo and another standard antidepressant. Effectiveness trials are
also warranted to better understand how use of the herb in clinical practice affects
outcomes of cost and quality.
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Appendix A
Depression Treatment Algorithm Questionnaire
The following questions were answered based on an average adult age 18 to 65, with a first time
diagnosis of major depression with mild to moderate severity who is treated with fluoxetine in the
outpatient setting.
Responses from expert panel on treatment of depression
PANEL MEMBER

1
TSH
LEVEL,
CBC, LFT

2
TSH
LEVEL

3
TSH
LEVEL

4
TSH,
CHEM-7

5
TSH

6
NONE

2. How do you assess or
diagnose depression?

DSM IV

DSM IV

DSM IV

BECK

DSM IV

DSM IV

3. What is the starting
dose of Prozac you
would prescribe?

10MG X1
WK,
20MG

20MG

20MG

20MG

10MG X
1WK,
20MG

20MG

4. When do you assess
response to therapy?

4 weeks

2-4 weeks

3 weeks

2 weeks

2 weeks

2-4
weeks

5. Are there any other
types of tests, such as
labs, that are performed
at this time?

CBC,
LFTs

No

No

LFTs

No

No

6. How many weeks of
therapy are necessary to
determine success or
failure on therapy?

4 weeks

4 weeks

6 weeks

4 to 6
weeks

2 to 4 weeks

4 weeks

7. What percentage of
patients (pts) respond to
fluoxetine by this time?

66.7%
(2/3)

60%

70% to
80%

50%

60%

66.7%
(2./3)

8. When a patient fails to
respond, what options
are considered?

Çdose,
change Rx

Çdose,
change Rx,
add therapy

Çdose,
change Rx

Çdose,
change Rx

Çdose,
change Rx,
add therapy

Çdose,
change
Rx

9. What percentage of
patients requires an
increase in dosage?

20%

25%

30%

30%

25%

25%

10. Once a response is
established, how often
does the patient return
for an assessment?

Every 2
months

Every 3 to 4
months

Every 3
months

Depends

Every 1 to 2
months x6
months

Every 3
to 4
months

1. After the initial
diagnosis, do you
perform any baseline
tests?
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Depression Treatment Algorithm Questionnaire (cont'd)
11. How long does the
average patient that
responds to Prozac
remain on the acute dose
of the drug?

9 months

12 months

6 to 12
months

6 to 9
months

6 to 12
months

12
months

12. Is there a period after
the symptoms are
controlled that the dose
is decreased?

Taper to
50% at
month 8

Taper to
50% last
month

No

No

No

13. What is the average
length of therapy for a
single depressive
episode?

9 months

12 months

6 to 12
months

12 months

6 to 12
months

Only if
pt
doesn’t
tolerate
dose
12
months

14. What are the most
commonly reported
adverse drug reactions
(ADRs)?

Edginess,
insomnia,
sexual
dysfxn.

Jitteriness,
nervousness,
HA, GI
upset,
insomnia

Nausea, GI
upset,
jitteriness,
sexual
dysfxn, HA

Nausea,
jitteriness,
insomnia,
HA, sexual
dysfxn.

Insomnia
GI upset,
HA

15. When do patients
most often complain of
ADRs?
16. Of these, which most
often cause
discontinuation of the
drug?

Week 1-2

Week 2 and
on

Week 1-2

Within 2
weeks

Insomnia,
jitteriness,
nervousness,
nausea,
sexual
dysfxn.
First few
days

Edginess

Rarely cause
DC

HA,
jitteriness

GI upset
and sexual
dysfxn.

Nausea and
insomnia

Rarely
cause DC

17. What percentage of
people discontinue
Prozac because of
ADRs?

20%

Less than
5%

20%

5%

10%-20%

Less than
1%

18. What, if any,
additional therapy do you
prescribe to treat ADRs?

Trazodone
50mg qhs

Ativan 1mg
or trazodone
50mg qhs

Trazodone
50mg qhs

None,
Change
therapy

Trazodone
50mg qhs

None

19. What percentage of
patients require this
therapy?

20%

15%

5-10%

5% change
therapy

10%

N/A

20. When a patient
discontinues therapy due
to ADRs, what other
therapies do you try?

Paxil
20mg or
Zoloft
50mg

Paxil 20mg
or Zoloft
50mg

Paxil 20mg
or
Wellbutrin
150mg

Wellbutrin
150mg

Paxil 20mg

Another
SSRI

21. Are there any ADRs
that require additional
medical care other than a
physician visit?

No

No

No

No

No

No
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Week 13

Depression Treatment Algorithm Questionnaire (cont'd)
22. Estimate the average
number of physician
visits a patient has in 1
year and for patients that
fail initial therapy.

5, 6 if fail
1st therapy

7

6, 7 if fail
1st therapy

6

6, 7-8 if fail
1st therapy

5, 6-7 if
fail and
ADRs

23. Do you refer (or
encourage) counseling
sessions for your
patients?

Yes

Yes

Yes

Yes

Yes

Yes

24. Estimate the number
of counseling visits a
patient has in 1 year.

4-6

5

Depends on
insurance

6

5

5

25. Are you familiar with
St. John's Wort and the
published trials?

Yes,
listened to
seminar

No

Somewhat

Yes

No

26. Do you prescribe the
herb?

No

No

No

No

No, but
heard it has
some
positive
effects
No

No

27. Are you aware of any
of your patients taking
the herb for depression?

Yes, many
take on
their own

No

Yes

No

No

No

28. Based on the
literature, do you feel the
herb is effective?

Possibly
in mild to
moderate
depression
No

N/A

Yes for
mild to
moderate
depression
No

Not enough
information

N/A

N/A

No

No

No

Regulation
by FDA
while
maintain
low cost

More
rigorous
trials,
regulation
of products

Studies
regarding
safety such
as drug
interactions

Accepted
standard
of care
by MDs

29. Would you prescribe
the herb based on
available data now
(1998)?
30. What information
would you like to see in
order to give you
confidence in prescribing
the herb?

Standardization
practices,
trials
against
standard
doses of
AD

No

Regulation
by FDA,
long-term (6
month)
trials,
comparisons
with SSRIs

KEY: AD = ANTIDEPRESSANT; ADR = ADVERSE DRUG REACTION;
CBC = COMPLETE BLOOD COUNT; CHEM-7 = SERUM BLOOD CHEMISTRY;
DC = DISCONTINUATION; DSM-IV = DIAGNOSTIC AND STATISTICAL MANUAL FOR
MENTAL DISORDERS-IV EDITION; GI = GASTROINTESTINAL; HA = HEADACHE;
LFT = LIVER FUNCTION TESTS; MD = MEDICAL DOCTOR; RX = TREATMENT;
TSH = THYROID STIMULATIN HORMONE
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Appendix B
Rolled Back Decision Tree

In the decision tree, it is revealed that initial treatment with St. John’s Wort is the most cost-effective option compared to treatment with fluoxetine.
Mdeval = cost of initial physician evaluation, MDfu = cost of physician follow-up visits, mdvisits = total number of physician visits,
Psycheval = cost of initial psychotherapy evaluation, therapy = cost of psychotherapy session, therapyvisits = total number of psychotherapy sessions,
Paxil = weekly cost of Paxil, paxil weeks = total number of weeks on Paxil, Prozac = weekly cost of fluoxetine, prozacweeks = total number of weeks
on fluoxetine, extract = weekly cost of St. John’s Wort, weeksextract = total number of weeks on St. John’s Wort, TSH = cost of measurement of
thyroid stimulating hormone serum level, Trazodone = weekly cost of trazodone, trazweeks = total number of weeks on trazodone, D/C Rx =
discontinue initial therapy, Rx = treatment, SE = side-effects, NC = noncompliant
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